Tang, Shou C., M.D.

Primary Practice Location:
University Hospital
2500 N. State St.
Jackson, MS 39216

Appointments: (888) 815-2005

Areas of Practice: Breast Cancers

Education

Board Certification:	Internal Medicine, Hematology & Oncology
Ph.D:	University of Alberta Faculty of Medicine and Dentistry
Medical Education:	West China University of Medical Sciences
Internship Program:	University of Alberta Faculty of Medicine and Dentistry
Residency Program:	Princess Margaret Hospital
Residency Program:	University of Alberta Faculty of Medicine and Dentistry

Current Positions

Professor , School of Medicine	11/2017 - Present
Associate Director , School of Medicine, Department of Cancer Institute	11/2017 - Present
Scientific Advisor , School of Medicine	2012 - Present
Visiting Professor , School of Medicine	2009 - Present
Adjunct Professor , School of Medicine	2008 - Present
Honorary Professor , School of Medicine	2003 - Present
External Research Consultant , School of Medicine	2002 - Present
Honorary Professor , School of Medicine	2002 - Present
The University of Mississippi Medical Center Jackson, Mississippi 39216

Education

Princess Margaret Hospital, MD, Medical Oncology	1995
University of Alberta, MD, Internal Medicine	1993
Misericordia Hospital, MD, General Medicine	1990
University of Alberta, PhD, Molecular Biology, Division of Medical Oncology	1983
West China University of Medical, MD, Honors Medicine	1982

Specialty Certification Licensure

Licensure, BAG-1 MAb, Santa Cruz Inc. San Diego, CA	2005 - 12/2005
Licensure, General License, Mississippi Board of Medical License	12/2017 - Present
Licensure, General License, Georgia Composite Medical Board	09/2013 - Present
Licensure, General License, Minnesota Medical Board	05/2010 - 05/2014
Licensure, General License, Colorado State Board of Medical Examiners	12/2007 - 12/2009
Licensure, General License, Arizona Medical Board	10/2006 - 10/2014
Licensure, General License, Florida Medical Board	2005 - 2016
Licensure, General License, Texas Medical Board	10/2005 - Present
Certification, Florida Faculty Teaching Certificate, Florida Medical Board	03/2002 - Present
Licensure, General License, Medical Board of Newfoundland	1995 - 2002
Licensure, General License, College of Physicians and Surgeons of Ontario	1993 - 1997
Licensure, General License, College of Physicians and Surgeons of Alberta	1991 - 2002
Certification, Educational Commission for Foreign Medical Graduates, United States Medical Licensing Examination Step I-III
Certification, Licentiate of Medical Council of Canada, Medical Council of Canada	07/1991 - Present
Certification, Specialist Certificate in Internal Medicine, Royal College of Physicians of Canada and Surgeons of Canada	11/1994 - Present
Certification, Certification of Special Competence in Medical Oncology, Royal College of Physicians and Surgeons of Canada Examination in Medical Oncology	09/1996 - Present
Certification, Fellow, Royal College of Physicians and Surgeons of Canada	01/1995 - Present
Certification, Fellow of the American College of Physicians, American College of Physicians-American Society of Internal Medicine	06/2002 - Present
Certification, Medical Oncology, American Board of Internal Medicine	2008 - 2018
Certification, Internal Medicine, American Board of Internal Medicine	1993 - 2003
Certification, Educational Commission for Foreign Medical Graduates	12/2001 - Present
Certification, Diplomate in Medical Oncology, American Board of Internal Medicine	2008 - 12/2018

Academic Appointments or Other Previous Appointments

Professor, Augusta University, School of Medicine, Department of Cancer Institute	2013 - 11/2017
US Oncology National Scientific Advisor	2010 - 2013
Co-Director, Breast Cancer Program, Minnesota Oncology	2010 - 2013
Director, Virginia Piper Cancer Institute, School of Medicine	2010 - 2013
Professor, University of Minnesota, School of Medicine	2010 - 2013
Professor, Division of Medicial Oncology, Department of Medicine, School of Medicine	2007 - 12/2009
Professor, Denver Health Medical Center, University of Colorado at Denver, School of Medicine	2007 - 12/2009
Director, Mayo Clinic Scottsdale, School of Medicine	2006 - 2007
Assistant Professor, University of Miami, School of Medicine	2002 - 2006
Associate Director, University of Miami, School of Medicine, Department of Cancer Institute	2002 - 2006
Visiting Professor of Medical Oncology, Sun Yat-sen, University of Medical Sciences, School of Medicine	1999 - 2001
Associate Professor, Memorial University of Newfoundland, School of Medicine	1999 - 2002
Director, Newfoundland Cancer Treatment and Research Foundation	1997 - 2002
Director, Newfoundland Cancer Treatment and Research Foundation, School of Medicine	1996 - 1997
Assistant Professor, Memorial University of Newfoundland, School of Medicine	1995 - 1999

Honors, Awards, and Recognition

Top Doctor in North Augusta, International Association of Internists (IAI)	2016
Marquis Who’s Who in Science and Engineering in the World, Marquis Who’s Who	2015
Chair and organizer, Second San Antonio Breast Cancer Symposium Review	2015
Chair and organizer, First San Antonio Breast Cancer Symposium Review	2014
Scientific Advisor, Sichuan Provincial Tumor Hospital	2012
Marquis Who's Who Listing in America, Marquis Who's Who Listing in America	2012
Co-Chair and Organizer: Update on Hematology and Oncology, Minneapolis, MN, USA, Co-Chair and Organizer: Update on Hematology and Oncology, Minneapolis, MN, USA	2011
Chair and Organizer, Fourth Asia Breast Cancer Summit	2010
Co-Chair and Organizer: Update on Breast Cancer, Minneapolis, MN, USA, Co-Chair and Organizer: Update on Breast Cancer, Minneapolis, MN, USA	2010
Visiting Professor, Xian Jiaotong University	2009
Founding President, US Chinese Anticancer Association (USCACA)	2009
Chair and Organizer, Third Asia Breast Cancer Summit	2009
Visiting professor, Wuxi 4th Municipal Hospital	2009
Chair and Organizer, Second Asia Breast Cancer Summit	2008
President-elect and Founding Member, US Chinese Anticancer Association (USCACA)	2008
2008 President and Founder, Chinese Earthquake Relief Fund	2008
Adjunct Professor, Tianjin Medical University	2008
Chair and Organizer, First Asia Breast Cancer Summit	2007
Chair and Founder, Asia International Breast Cancer Summit	2007
2007-2008 Chinese-American Hematology/Oncology Network (CAHON) Education, 2007-2008 Chinese-American Hematology/Oncology Network (CAHON) Education	2007
Visiting Professor, Beijing Union Medical University	2006
Organizer, Asia Breast Cancer Summit	2006
Co-Director, Second Inter-America Breast Cancer Conference	2004
Visiting professor, Fudan University Cancer Hospital	2004
Honorary Professor, Liaoning Provincial Cancer Hospital	2003
Honorary Professor, West China University of Medical Science Cancer Center	2003
Breast Cancer Session Chair, Asian Clinical Oncology Society Annual Meeting	2003
Chair, Cancer Management Committee, Newfoundland Cancer Treatment	2002
Co-Chair, Miami International Conference on Lung Cancer	2002
Co-Director, First Inter-American Breast Cancer Conference	2002
Nucleus Group of the Specialty Committee in Medical Oncology, The Royal College of Physicians and Surgeons of Canada	2001
Canadian Oncology Leadership Conference, Canadian Oncology Leadership Conference	2000
Breast Cancer Case Study Facilitator, Breast Cancer Case Study Facilitator	1999
Chair, Eprex Consensus Conference	1998
Leadership in Hormonal Management of Breast Cancer, Leadership in Hormonal Management of Breast Cancer	1998
Breast Cancer International Research Group (BCIRG) Scientific Committee, Breast Cancer International Research Group (BCIRG) Scientific Committee	1998
Leader, Systemic Therapy Program	1998
Scientific Advisory Board, MedMira Laboratory	1997
Physician Management Institute Certification, Physician Management Institute Certification	1997
Chair and Founder, Atlantic Canada Oncology Group (ACOG)	1996
Organizer and Chair, Annual Atlantic Canada Oncology Group Winter	1996
Alberta Heritage Foundation for Medical Research (AHFMR) Post-Doctoral Fellowship, AHFMR	1987
Alberta Heritage Foundation for Medical Research (AHFMR) Post-Doctoral Fellowship, AHFMR	1986
Alberta Heritage Foundation for Medical Research (AHFMR) Post-Doctoral Fellowship, AHFMR	1985
Alberta Heritage Foundation for Medical Research (AHFMR) Post-Doctoral Fellowship, AHFMR	1984
Alberta Heritage Foundation for Medical Research (AHFMR) Post-Doctoral Fellowship, AHFMR	1983
Chinese Ministry of Education Scholarship for Overseas Graduate Studies, Chinese Ministry of Education	1982
Honors Medical Student Award, West China University of Medical Sciences	1979

Professional Membership and Service

American Association for Cancer Research, Member	2017 - Present
Georgia Society of Clinical Oncology (GASCO), Member	2014 - Present
Southwest Oncology Group (SWOG), Member	2013 - Present
Minnesota Medical Association and Twin Cities Medical Society, Member	2010 - 2013
US Oncology Scientific Advisory Committee and Breast Cancer Committee, Member	2010 - 2012
Chinese Anti-cancer Association (USCACA), Officer-President	2009 - Present
Eastern Cooperative Oncology Group (ECOG), Member	2003 - 2009
Chinese-American Hematology/Oncology Network (CAHON), Member	2003 - Present
Navelbine Lung Cancer, Board of Advisors of a Company, Navelbine Lung Cancer Advisory Board Meeting	1999 - 2000
Breast Cancer Advisory Board, Board of Advisors of a Company, Breast Cancer Advisory Board	1999 - 2000
Consensus Meeting on the Development of Orzel, Member, Consensus Meeting on the Development of Orzel	1998 - 1999
Meeting on Herceptin/Capecitabine, Board of Advisors of a Company, Advisory Board Meeting on Herceptin/Capecitabine	1998 - 1999
Oncology Academy, Member, Oncology Academy Meeting	1998 - 1999
Eprex Consensus Conference, Member, Eprex Consensus Conference	1998 - 1999
Fellow of Royal College of Physicians and Surgeons of Canada (FRCPC), Member	1997 - Present
Fellow of the American College of Physicians (FACP), Member	1997 - Present
Atlantic Canada Oncology Group, Officer-President	1996 - 2002
Memorial University of Newfoundland, Member	1995 - 2002
Canadian Association of Medical Oncologists, Member	1995 - 2002
American College of Physicians, Member	1995 - Present
American Society of Clinical Oncology, Member	1995 - Present
Canadian Medical Association, Member	1990 - 2002
International Journal of Cancer Studies and Research (IJCR), Editorial Boards
Chinese Journal of Lung Cancer, Editorial Board, Editorial Board
Journal of Modern Oncology, Editorial Board, Editorial Board
Journal of Cancer Studies and Therapy, Editorial Board, Editorial Board
International Journal of Cancer and Clinical Research, Associate Editor

Committee Service

MEDICAL CENTER-RESEARCH ADVISORY, Member	2018 - Present
MEDICAL CENTER-RESEARCH ADVISORY, Member	2018 - Present
MEDICAL CENTER-RESEARCH ADVISORY, Chair	2017 - Present
San Antonio Breast Cancer Symposium Abstract Review Committee, Member	2016 - Present
Changing landscape of chemotherapy in oncology, Amgen Global Advisory Board Amsterdam, Holland, Member	2016 - 2016
Abbvie Breast Cancer Advisory Board, Chicago, Member	2016 - 2016
Southwestern Oncology Group (SWOG) Breast Cancer Committee, Member	2015 - Present
Protocol Review and Monitor Committee (PRMC), Georgia Regents University (GRU) Cancer Center, Member	2013 - 2017
Novartis Bolero Advisory Board, Member	2012 - 2012
Genomic Health Advisory Board, Member	2012 - 2012
Amgen Advisory Board, Member	2012 - 2012
Celgene Advisory Board	2012 - 2012
Genentech Bevacizumab and TDM-1 Advisory Board, Member	2012 - 2012
Expert Input Summit, Merck, Cambridge, MA., Member	2012 - 2012
BMS Breast Cancer Opinion Leader Steering Committee, San Antonio, Member	2012 - 2012
US Oncology Breast Cancer Leadership Committee, Houston, TX, Member	2010 - 2013
Novartis BIG 1-98 USA Steering Committee, Washington, Member	2008 - 2008
Novartis Advisory Board, Dallas, Member	2008 - 2008
Genentech Advisory Board, Chicago, Member	2008 - 2008
Sanofi-Aventis Advisory Board, San Francisco	2008 - 2008
Sanofi-Aventis Advisory Board, Chicago, Member	2008 - 2008
Novartis Breast Advisory Board, Dallas, TX, Member	2006 - 2006
Abraxis Breast Cancer Advisory/Speaker Meeting, Dallas, Texas, Member	2005 - 2005
Abraxis Advisory Board Meeting, New York City	2005 - 2005
African Oncology Advisory Board, Nairobi, Kenya, Member	2005 - 2005
Pfizer Breast Cancer Prevention Advisory Board, Cancun, Mexico, Member	2004 - 2004
Abraxis Advisory Board, San Francisco, CA, Member	2004 - 2004
HOPE (Orthobiotech) Speakers Bureau/Advisory Board, Dallas, TX, Member	2004 - 2004
Pfizer Breast Cancer Advisory Board, Dallas, TX, Member	2004 - 2004
Ligand Advisory Board, Dallas, Member	2004 - 2004
Pharmacia Third Annual Breast Cancer Advisory Board Meeting, Telluride, Member	2003 - 2003
BMS Lung Cancer Summit Meeting, Las Vegas, Member	2003 - 2003
Aventis Lung Cancer Advisory Board, Washington DC, Member	2003 - 2003
Amgen Research Exchange Program, Thousand Oaks, California, Member	2003 - 2003
Aventis Regional Advisory Board, Naples, Florida, Member	2003 - 2003
Pfizer Breast Cancer Regional Advisory Board, Washington DC, Member	2003 - 2003
Eli Lilly Breast Cancer Advisory Board, Phoenix, AZ, Member	2003 - 2003
Roche Breast Cancer Advisory Board, Chicago, Member	2003 - 2003
Aventis Breast Cancer Investigator Meeting, Chicago, Member	2003 - 2003
Amgen Investigators Meeting, Chicago, Member	2003 - 2003
Pfizer Regional Advisory Board, Las Vegas, Member	2003 - 2003
Merck Emend Advisory Board, New York City, Member	2003 - 2003
GSK Dual EGFR Inhibitor Advisory Board, San Francisco, Member	2003 - 2003
BMS Breast Cancer Speaker Meeting, New York City, Member	2003 - 2003
Eli Lilly Lung Cancer Advisory Board, Vancouver, Canada, Member	2003 - 2003
Pfizer Breast Cancer Think Tank Meeting, Avon, Colorado, Member	2003 - 2003
BMS Aranesp/Neulasta Advisory Board, New York City, Member	2003 - 2003
Novartis Breast Cancer Advisory Board, Atlanta, Georgia, Member	2003 - 2003
Pfizer Aromasin Advisory Board, San Antonio, Texas, Member	2003 - 2003
Pharmacia Breast Cancer Advisory Board, San Antonio, Member	2002 - 2002
Hycamtin Advisory Board, Orlando, Florida, Member	2002 - 2002
Oncology Faculty Development: Navelbine Speakers Program, Chicago, Illinois, Member	2002 - 2002
Taxotere Regional Advisory Board Meeting, Pinehurst, North Carolina, Member	2002 - 2002
Glaxo Metastatic Breast Cancer Local Advisory Board, Miami, Florida, Member	2002 - 2002
Novartis AREA Advisory Board, Miami, Florida, Member	2002 - 2002
AstraZeneca Oncology Advisory Board, Palm Beach, Florida, Member	2002 - 2002
Breast Cancer International Research Group (BCIRG) Scientific Advisory Board Meeting, Laguna, California, Member	2002 - 2002
AstraZeneca National Annual Meeting Medical Consultant, Los Angeles, Member	2002 - 2002
Advances and Controversies in the Management of Breast and Colorectal Cancers, NOCR Roche Tumor Advisory Board, Coral Gable, Florida, Member	2002 - 2002
Ligand Advisory Board, Key Biscayne, Florida, Member	2002 - 2002
Eli Lilly Oncology Advisory Board, Miami, Florida, Member	2002 - 2002
Doxil Advisory Board, New Orleans, Louisiana, Member	2002 - 2002
Pharmacia & Upjohn Advisory Board Meeting on Exemestane, Vancouver, Member	2001 - 2001
Impact Breast Cancer AstraZeneca Advisory Board Meeting, Miami	2001 - 2001
Breast Cancer Medical Ambassador Program to the 11th European Cancer Conference, Lisbon, Portugal, Member	2001 - 2001
Femara Clinical Consultants Meeting, San Antonio, Member	2000 - 2000
Eprex Lung Cancer Advisory Board Meeting, Corner Brook, Member	2000 - 2000
Herceptin Advisory Board Meeting, Montreal, Member	2000 - 2000
Gemcitabine Advisory Board Meeting, Miami, Member	2000 - 2000
Taxotere Advisory Board Meeting, New York City, Member	2000 - 2000
Herceptin Advisory Board, Toronto, Member	1999 - 1999
Eprex Lung Cancer Advisory Board Meeting, Toronto, Member	1999 - 1999
Navelbine Lung Cancer Advisory Board Meeting, Toronto, Member	1999 - 1999
Breast Cancer Advisory Board, Vienna, Member	1999 - 1999
Consensus Meeting on the Development of Orzel, Florida, Member	1998 - 1998
Eprex Consensus Conference, St. Johns, Member	1998 - 1998
Advisory Board Meeting on Herceptin/Capecitabine, Member	1998 - 1998
National Cancer Institute of Canada Grant Review Committee, Member	1997 - 1999
Canadian Inter-provincial Chemotherapy Utilization Committee, Member	1995 - 2002

Community Service

Annual Pink Pumpkin Breast Cancer Fund raiser, Georgia, Participant	10/2014 - 10/2017
Chinese Free Clinic of Minnesota, Volunteer Physician	2010 - 12/2013
China Wenchuan Earthquake Fund, Chair	05/2008 - 08/2008
Annual Susan G Komen Run, Participant	10/2002 - 10/2005

Other Service

External Reviewer, Gene Therapy	2017 - Present
External Reviewer, Oncotarget	2016 - Present
External Reviewer, Oncotarget	2015 - Present
External Reviewer, Biochimica et Biophysica Acta (BBA)	2014 - Present
External Reviewer, Oncotarget and Therapy	2014 - Present
External Reviewer, Biochemical Biophysical Research Communications (BBRC)	2014 - Present
External Reviewer, Cell Biochemistry and Function	2014 - Present
International Journal of Cancer Studies & Research (IJCR)	2013 - Present
Journal of Cancer Studies and Therapy	2013 - Present
International Journal of Cancer and Clinical Research	2013 - Present
External Reviewer, Oncogene	2013 - Present
Bolero Global Development Advisory Committee, Committee Member	2012 - Present
External Reviewer, Cancer Letters	2012 - Present
US Oncology Breast Cancer Committee, Committee Member	2012 - Present
Minnesota Oncology Breast Cancer Program, Program Co-Chair	2011 - Present
External Reviewer, Cancer Letters	2010 - Present
Allina Breast Committee, Committee Member	2010 - Present
US Oncology Scientific Advisory Committee, Committee Member	2010 - Present
US Chinese Anti-Cancer Association (USCACA), USCACA President	2008 - 2010
Asia International Breast Cancer Summit, Summitt Chair	2007 - 2010
External reviewer, Journal of Hematology and Oncology	2007 - Present
External reviewer, Chemotherapy, Switzerland	2007 - Present
Journal of Modern Oncology	2004 - Present
External Reviewer, Biochemistry and Cell Biology, Canada	2004 - Present
ECOG Lung Cancer Biology Subcommittee, Subcommittee Member	2003 - 2005
ECOG Lung Cancer Core Committee, Core Committee Member	2003 - 2005
Eastern Cooperative Oncology Group (ECOG), ECOG Member	2003 - 2005
Pharmacy and Therapeutic Committee, Sylvester Comprehensive Cancer Center, Pharmacy and Therapeutic Committee Member, University of Miami	2003 - 2005
ECOG Lung Cancer Core Committee Meeting, Committee Meeting Member, Chicago	2003 - Present
BCIRG Scientific Advisory Board, Advisory Board Member, Chicago	2003 - Present
Protocol Review Committee, Sylvester Comprehensive Cancer Center, Protocol Review Committee Member, University of Miami	2002 - 2005
External Advisory Committee, Sylvester Comprehensive Cancer Center, External Advisory Committee Member, University of Miami	2002 - 2005
Site Disease Group Leadership Committee, Sylvester Comprehensive Cancer, Site Disease Group Leadership Committee Member, University of Miami	2002 - 2005
Executive Committee, Sylvester Comprehensive Cancer Center, Executive Committee Member, University of Miami	2002 - 2005
Peer Review Committee, Sylvester Comprehensive Cancer Center Developmental, Peer Review Committee	2002 - 2005
External reviewer, Cancer Research, Philadelphia, USA	2002 - Present
External reviewer, British Journal of Cancer, UK	2002 - Present
Editor, Lung Cancer, Chinese Edition, Chengdu, China	2002 - Present
Breast Cancer International Research Group (BCIRG) Scientific Advisory Board, Scientific Advisory Board Member	2002 - Present
External Grant Reviewer, Saskatchewan Cancer Agency, Saskatoon, Scientific Committee	08/2001 - Present
Canadian Lung Cancer Consultants Meeting, Miami, Consultant	02/2001 - Present
External Reviewer, Breastlink.Com, UCLA, Los Angeles, USA	2001 - Present
Internal Grant Reviewer, Memorial University of Newfoundland Cancer Research	2001 - Present
Breast Cancer International Research Group (BCIRG) Scientific Advisory Board, Scientific Advisory Board Meeting	12/2000 - Present
Research Council Committee, Newfoundland and Labrador Center for Applied, Research Council Committee	2000 - 2002
MedMira Scientific Advisory Board Meeting, Scientific Advisory Board Meeting	2000 - Present
Board of Directors, MedMira Laboratory, Nova Scotia, Canada	2000 - 2008
External Reviewer, Journal of Cell Science, Cambridge, UK	2000 - Present
BCIRG Scientific Advisory Board Meeting, Edmonton, Scientific Advisory Board Meeting	12/1999 - Present
Canadian Association of Medical Oncologists (CAMO) Fellowship Committee, Fellowship Committee	1999 - 2000
Scientific Officer, NCIC Grant Review Panel	1999 - 2000
Canadian Oncology Leadership Conference, Palm Springs	1999 - Present
Canadian - USA Oncology Exchange Program Memorial Sloan-Kettering Institute, New York City	1999 - Present
External Grant Reviewer, Alberta Cancer Board	1999 - Present
BCIRG Scientific Advisory Board Meeting, Edmonton, Scientific Advisory Board Meeting	06/1998 - Present
First p53 Gene Therapy Expert Summit, Kenilworth, NI, Summit	03/1998 - Present
Interprovincial Chemotherapy Drug Strategy Steering Committee	1998 - 2002
External Grant Reviewer, Northern Ontario Regional Cancer Center	1998 - Present
External Reviewer, Journal of Cancer Prevention and Control	1998 - Present
Medical Council of Canada Qualifying Examination Part Two Examiner	1997 - Present
Chinese Journal of Lung Cancer	1996 - Present
Provision and Evaluation of Exam Questions for 1997-1998 Medical Oncology Examination by American Board of Internal Medicine	1996 - Present
MRC External Grant Reviewer, Medical Research Council of Canada	1996 - Present

Publications

2017 American Society of Clinical Oncology (ASCO) Presentation
Houssein Talal Abdul Sater, Ramses F. Sadek, Li fang Zhang, Aaron Gopal, Jean-Pierre Blaize, David Yashar, Reena Patel, Swetha Aribindi, Hiral S Patel, Shou-Ching Tang Validity of 1% Hormonal Positivity Cutoff by American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines at Georgia Cancer Center	2017
2017 American Society of Clinical Oncology (ASCO) Conference Presentation
Shou-Ching Tang, Priyanka Raval, Mohamad Bassam Sonbol, Josh David Simmons, Rohini Chintalapally, Natasha Savage, Ravindra B. Kolhe, Eiko Kitamura, Chang-Sheng Chang, Mark Robert Keaton, Nita J. Maihle, Sangmi Kim PI3K Mutation and Effect of Aspirin Use in Breast Cancer	2017
Proceedings of the American Association for Cancer Research
Tang S-C, Xiong J, Chen J, Chernenko G, Beck J, Liu H Antisense BAG-1 Sensitizes HeLa Cells to Apoptosis by Multiple Apoptotic Pathways Proc Am Assoc Can Res, 44(2):1219, 2003	2003
Letter
Zhang Q, Tang SC, Liu H, Early stage triple negative and HER2 overexpression breast cancers have similar survivals in Chinese patients. The breast journal, 2012 May-Jun;18(3):286-8
Journal Article
XUE, LU; Maihle, Nita; Yu, Xiaolin; Tang, Shou-Ching; Liu, Hong Yan Synergistic targeting HER2 and EGFR with a bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth Molecular Pharmaceutics, 17 Sept 2018.	2018
Meng Wang, Yuan Li, Guo-Dong Xiao, Xiao-Qiang Zheng, Ji-Chang Wang, Chong-Wen Xu, Sida Qin, Hong Ren, Shou-Ching Tang, Xin Sun H19 Regulation of Estrogen Induction of Symmetric Division is achieved by Antagonizing Let-7c in Breast Cancer Stem-like Cells Cell Proliferation, 20 Sept 2018.	2018
Ibrahim Sadek, Mark Keaton, Nita Maihle and Shou-Ching Tang Anti-HER2 therapy in patients with trastuzumab-induced severe cardiac dysfunction Genes and Diseases, August, 2017	2017
Shah Gandhi, Arpita; Mensah, Felix; Titus, Lauren; Bradley, Amanda; Schlafstein, Ashley; Tang, Shou-Ching A single, low-dose cyclophosphamide associated severe hyponatremia with seizures: a case report J. Community and Palliative Oncol. 15, 37-39 March, 2017	2017
Shou-Ching Tang and Fei Li Targeting metastatic breast cancer with ANG1005, a paclitaxel-pepide conjugate that crosses the blood-brain-barrier (BBB) Genes and Diseases, Vol. 4, Issue 1, March 2017, Pages 1–3	2017
Khurram Tariq, Ryan Keen, Karen Draper and Shou-Ching Tang Unfortunate Accident or a Blessing in Disguise?: Dramatic response to incidental intra-thoracic delivery of anti-HER2 regimen J. Global Oncology, published on line ahead of print, 2017	2017
Badi Edmond El Osta, Fengjiao Hu, Ramses F. Sadek, Rohini Chintalapally, Shou-Ching Tang All check point inhibitors are not created equal: A meta-analysis of immune-related adverse events (irAE) from cancer clinical trials Critical Rev. Hem. Oncl. , published on line ahead of print, 2017	2017
Mark Floyd, Badi El Osta and Shou-Ching Tang First report of Parkinsonism associated with indoximod, an immune-modulating agent DOI: 10.1200/JGO.2016.007492 Journal of Global Oncology - published online before print November 30, 2016	2016
Sun X, Xu C, Tang SC, Wang J, Wang H, Wang P, Du N, Qin S, Li G, Xu S,Tao Z, Liu D, Ren H Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells Cancer Gene Ther. 2016 Apr; 23(4):83-9. Doi: 10.1038/cgt.2016.3.Epub 2016 Mar 18	2016
Mark Keaton, Debu Tripathy, Joyce O’Shaughnessy, Shou-Ching Tang Highlights of the 2015 San Antonio Breast Cancer Symposium Genes and Disease, 3-2, 110–113 Online March 2016.	2016
Fei Li, Lin Zhang, Shou-Ching Tang Revisiting vitamin C in cancer therapy: Is “C” for cure or wishful thinking? Genes and Diseases, 3-1, March 2016, 1-2	2016
Wang J, Li G, Wang Y, Tang S, Sun X, Feng X, Li Y, Bao G, Li P, Mao X, Wang M, Liu P Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1a/VEGF secretion axis Oncotarget 2015 Dec 29; 6 (42):44579-92	2015
Jian Liu, Ning Du, Huangzhen Wang, Xin Wang, Peili Wang, Jia Zhang, Gang Li, Jing Zhang, Sida Qin, Chongwen Xu, Shou-Ching Tang, Xin Sun, Boxiang Zang, Dapeng Liu, and Hong Ren P53 Sensitizes Breast Cancer Stem Cells to Let-7 miRNAs Induced Repression International Journal of Cancer and Clinical Research, 1.1-8, 2014	2014
Tang S-C. Current approach in the adjuvant hormonal therapy of early breast cancer J. Breast Cancer. 12, suppl. 2, 110-111, 2009	2009
Pennock, G., Fishman, M., Gonzales, R, Thmopson, B., Huang, S., Tang, S., Rhode, P. and Wong. H Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies Clin. Oncol 27:15s, 2009	2009
Tang S-C Comment on: Meta-analysis of taxanes in early breast cancer Breast Diseases: A Year Book Quarterly 2008;19(2):pp.	2008
Rizwan Shaikh, Khurram Tariq, Suash Sharma and Shou-Ching Tang Metastatic Breast Cancer presenting as Orbital Mass: Case Report and Literature Review DOI: 10.1200/JGO.2017.009282 Journal of Global Oncology - published online before print March 24, 2017	2007
Tang S-C Current advancement in the hormonal adjuvant therapy of early breast cancer Practical Journal of Clinical Medicine; vol. 3, p 18. 2006	2006
Xin Sun, Shou-Ching Tang, Chongwen XU, Lianjin Jin, Ersilia Mirabelli, Jie Zhou, Qi Qin, Hong Ren Dicer regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1 Journal of Cellular and Molecular Medicine, 2005 in press.	2005
Xin Sun, Chongwen XU, Ning Du, Sida Qin, Ersilia Mirabelli, Shou Ching Tang, Hong Ren Akt1 is required for p53 enhanced sensitivity of breast cancer cells to chemotherapy induced inhibition. Oncology Letter, 2005 in press.	2005
Martin M, Pienkowski T, Mackey J, Pawliki M, Gustalla J, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Haisworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang S-C, Colwell B, Prady C, Provencher L, Walde D, Rodriquez-Lescure A, Hugh J, Nabholtz J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C Adjuvant docetaxel for node-positive breast cancer New E. J. Med, 352, 2302-2313, 2005.	2005
Tang SC Targeted therapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2004 Aug 20;7(4):284-9. doi: 10.3779/j.issn.1009-3419.2004.04.04.	2004
Tang S-C, Beck J, Chernenko G, Murphy S, Robb D, Watson P, Khalifa M Expression of BAG-1 correlates with Bcl-2, p53, differentiation, estrogen receptor and progesterone receptor in invasive breast cancer Breast Can. Res. and Treat, 84, 203-13 2004	2004
Tang S-C Targeted Therapy in Non-small Cell Lung Cancer Chinese J. Lung Cancer, 7, 284-289, 2004.	2004
Tang S-C, Huang Q, Chen J Differential anti-apoptotic functions of BAG-1 isoforms in breast cancer cells in the presence of estrogen and anti-estrogen Breast Can Res. Treat., 88,1,73, 2004.	2004
Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (Tang S-C) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer, Nov; 98(9):1802-10, 2003	2003
Tang S-C Limited stage small cell lung cancer in a 65-year-old woman The Oncology Treatment Reporter, June, 1-4, 2003.	2003
Tang S-C Differential anti-apoptotic function of BAG-1 isoforms in human malignancy Recent Research Developments in Biophysics & Biochemistry, 3:427-444, 2003	2003
Raez LE, Cassileth P, Fisher E, Padmanabhan S, Sridhar K, Tang S-C, Baldie P, Podack E CD8 T cell and Clinical Response of Patients with Advanced Non Small Cell Lung Carcinoma to Immunization with Gene Modified Allogeneic Cells Lung Cancer 41, 2, 46, 2003.	2003
Padmanabhan S, Raez LE, Santos E, Rosado F, Tang S-C, Ramos JC, Baldie P, Farfan N, Sridhar K Phase I trial of Topotecan, Adriamycin and Vincristine (TAV) in patients with Small (SCLC) and Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 41, 2, 233, 2003.	2003
Xiong J, Chen J, Chernenko G, Tang S-C Sensitization to apoptosis by antisense BAG-1 is mediated by multiple apoptotic pathways BBRC, 314, 585-591, 2003	2003
Tang S-C Optimizing adjuvant therapy in early breast cancer: current data and future direction Cancer Res. and Treat., 35, 5, 14, 2003	2003
Raez LE, Cassileth PA, Schlesselman J, Padmanabhan S, Fisher E, Baldie P, Sridhar K, Tang S-C, Podak E Immunotherapy with gene-modified allogenic cells successfully induced CD8 T cell and clinical responses in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 41(2):S46-S47, 2003	2003
Padmanabhan S, Raez LE, Santos E, Tang S-C, Ramos JC, Rosado F, Baldie P, Farfan N, Sridhar K Phase I clinical trial with Topotecan, Adriamycin and Vincristine (TAV) in patients with advanced small (SCLC) and non-small cell lung cancer (NSCLC) Lung Cancer, 41(2):S233, 2003	2003
Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists’ Group (Tang S-C) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial 2002 Jun; 359(9324):2131-9.	2002
Robb D, Syble D, Tang S-C Expression of Mcl-1 predicts absence of local-regional recurrence of breast carcinoma. Breast Can. Res. Treat. 76,1-28, 2002	2002
Witcher M, Yang X, Pater A, Tang S-C BAG-1 p50 isoform interacts with the vitamin D receptor and its cellular overexpression inhibits the vitamin D pathway Exp. Cell Res., 265, 167-173, 2001.	2001
Rorke S, Murphy S, Khalifa M, Tang S-C Prognostic significance of BAG-1 expression in non-small cell lung cancer Int. J. Cancer, 2001, 95, 317-322, 2001	2001
Weerasinghe P, Hallock S, Tang S-C, Liepins A Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death Cell Biol. Toxicol., 17, 371-181, 2001.	2001
Weerasinghe P, Hallock S, Tang S-C, Leipins A Sanguinarine induced cell death in K562 but not in high Bcl-2-expressing JM1 cells Pathol. Res. Pract., 197, 717-726, 2001.	2001
Tang S-C Emerging Role of Letrozole in Metastatic Breast Cancer. Current Oncology, 8(2), 85-87, 2001.	2001
Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang S-C, McKenzie M, Couture F Epoetin alfa therapy increase hemoglobin levels and improves quality life in patients with cancer-related anemia who are not receiving chemotherapy the Canadian EPREX Oncology Study Group. J. Clin. Oncol., 19, 4126-4134, 2001.	2001
Twelves C, Fumoleau P, Jones SE, Artim RA, Froimtchuk MJ, Inbar MJ, Kroener JF, Martin M, Mennel RG, Tang S-C, Tanato M, VanHazel GA Adding Xeloda (capecitabine) to docetaxel significantly improves survival and does not compromise quality of life in patients with metastatic breast cancer. Breast Can Res Treat, 69(3):307, 2001	2001
Ding Z, Yang X, Pater A, Tang S-C Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of anti-apoptotic proteins in human cervical multidrug-resistant cells Biochemical and Biophysical Research Communications, 270, 415-420, 2000	2000
Tang S-C Small cell lung cancer: The promise of the new drugs Current Oncology, 7, 193-194, 2000	2000
Ding Z, Yang X, Chernenko G, Tang S-C, Pater A Human papillomavirus type 16-immortalized endocervical cells selected for resistance to cisplatin are malignantly transformed and have a multidrug resistance phenotype Int. J. Cancer, 87, 818-823, 2000	2000
Tang S-C, Champion P Third Atlantic Canada Oncology Group Winter Symposium Current Oncology, 6, 180-185, 1999	1999
Tang S-C, Shahata N, Chernenko G, Khalifa M, Wang X. Expression of BAG-1 in invasive breast carcinoma J. Clin. Oncol., 17, 1710-1719, 1999	1999
Tang S-C, Shahata N, Chernenko G, Khalifa M, Wang X Expression of BAG-1 in invasive breast carcinoma J. Clin. Oncol., 17, 1710-1719, 1999	1999
Yang X, Pater A, Tang S-C Cloning and characterization of the human BAG-1 gene promoter: Upregulation by tumor-derived p53 mutants Oncogene, 18, 4546-4553, 1999	1999
Shehata N, Pater A, Tang S-C Prolonged, severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyridine dehydrogenase deficiency Cancer Inv., 17(3), 201-205, 1999	1999
Yang X, Hao Y, Ferenzy A, Tang S-C, Pater A Overexpression of anti-apoptotic gene BAG-1 in human cervical cancer Exp. Cell. Res., 247, 200-207, 1999	1999
Yang X, Hao Y, Pater A, Tang S-C Differential expression of anti-apoptotic gene BAG-1 in human breast normal and cancer cell lines and tissues Clin. Cancer Res., 5, 1816-1822, 1999	1999
Tang S-C Prognostic value of BAG-1 in invasive breast cancer Current Oncol., 5, 195-201, 1998	1998
Yang X, Pater MM, Pater A, Tang S-C Human BAG-1/RAP 46 is generated as four isoforms by alternative translation initiation and overexpressed in cancer cells Oncogene, 17, 981-989, 1998	1998
Yang X, Hao Y, Pater MM, Tang S-C, Pater A Enhanced protein expression of anti-apoptotic genes in HPV-immortalized and CSC-transformed human endocervical cells: correlation with resistance to apoptosis induced by DNA damage Mol. Carcinogenesis, 22, 95-101, 1998	1998
Sun Q, Tang S-C, Pater MM, Pater A Different HPV-16 E6/E7 oncogene expression patterns in epithelia reconstructed from HPV-16 immortalized human endocervical cells and genital keratinocytes Oncogene, 15, 2399-2408, 1997	1997
Tang, S-C Role of systemic chemotherapy in non-small cell lung cancer Current Oncology, 4, 77-82, 1997	1997
Nakao Y, Yang X, Yokoyama M, Fereczy A, Tang S-C, Pater MM, Pater A Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation Br. J. Cancer, 75, 1410-1416, 1997	1997
Khare S, Pater MM, Tang S-C, Pater A Effect of glucocorticoid hormones on viral gene expression, growth and dysplastic differentiation in HPV 16-immortalized ectocervical cells Exp. Cell Res., 232, 353-360, 1997	1997
Yang X, Nakao Y, Pater M, Tang S-C, Pater A Expression of cellular genes in PHV16-immortalized and cigarette smoke condensate-transformed human endocervical cells J. Cell Biochem., 66, 309-321, 1997	1997
Khare S, Tang S-C, Pater MM, Pater A Up-regulation of hormone response of human papillomavirus type 16 expression and increased DNA-protein binding by consensus mutations of viral glucocorticoid response element J. Med. Viol., 50, 254-262, 1996	1996
Khare S, Tang S-C, Pater MM, Pater A Cofactors with HPV in infection and oncogenesis Papillomavirus Rev., 239-246, 1996	1996
Kumar KU, Devireddy LR, Tang S-C, Pater A, Pater MM Human JC virus nuclear factor 1 binding motifs and large tumor antigen region required for transactivation of late promoter J. Neurochem., 67, 473-481, 1996	1996
Tang S-C, Hewitt K, Berinstein N Immunosuppression toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma Leukemia and Lymphoma, 24, 93-101, 1996	1996
Kumar K, Tang S-C, Pater MM, Pater A Glial and muscle embryonal carcinoma cell-specific independent regulation of expression of human JC virus early promoter by cyclic AMP response elements and adjacent nuclear factor 1 binding sites. J. Med. Viol., 49, 199-204, 1996	1996
Berinstein NL, Tang S-C, Hewitt K Objective clinical responses in patients with progressive/recurrent low grade lymphoma treated with Campath-1H monoclonal antibody Blood, 84(10):638, 1994.	1994
Tang S-C, Visser L, Hepperle B, Hanson J, Poppema S Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases J. Clin. Oncol., 12, 149-154, 1994	1990
Seehafer JG, Slupsky JR, Tang S-C, Masellis-Smith A, Shaw AR Myristic acid is incorporated into the two acylatable domains of the functional glycoprotein CD9 in ester, but not in amide bonds Biochim Biophys Acta, 1039(2):218-26, 1990	1990
Seehafer JG, Slupsky JR, Tang S-C, Shaw AR The functional cell surface glycoprotein CD9 is distinguished by being the major fatty acid acylated and a major iodinated cell surface component of the human platelet. Biochim, Biophys. Acta., 952, 92-100, 1988	1988
Seehafer JG, Tang S-C, Slupsky JR, Shaw AR. The functional glycoprotein CD9 is variably acylated: Localization of the variably acylated region to a membrane-associated peptide containing the binding site for the agonistic monoclonal antibody 50H.19. Biophys. Acta., 957, 399-410, 1988.	1988
Tang S-C, Jing GZ, Liu AP, Wu XN, Leung WC. A new approach for chemical-enzymatic synthesis of IFN-Y gene and strategy of site-specific mutagenesis. LM. 1984; P15-27.	1984
Leung WC, Tang S-C, Liu AP, Jing GZ, Wu XN Protein engineering of IFN-Y by using novel approaches for chemical-enzymatic gene synthesis and fragment replacement method for site-specific mutagenesis. Antiviral Research. 4:1-3, 1984	1984
Slupsky JS, Seehafer JG, Tang S-C, Masellis-Smith A, Shaw AR Evidence that monoclonal antibodies against CD9 antigen induce specific association between CD9 and the platelet glycoprotein IIb-IIIa complex. J. Biol. Chem., 264, 12289-12293, 1989
Yu X, Ghamande S, Liu H, Xue L, Zhao S, Tan W, Zhao L, Tang SC, Wu D, Korkaya H, Maihle NJ, Liu HY, Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2⁺ Breast Cancer. Molecular therapy. Nucleic acids, 2018 Mar 2;10:317-330	2018
Li G, Qin S, Sun X, Wang J, Zhang Y, Zhang J, Zhang J, Tang SC, Ren H, Retrospective observational cohort study on cosmetic outcome of using Ti-Ni memory alloy wire for intradermal suture following mastectomy in patients with breast cancer. Oncology letters, 2018 Feb;15(2):2465-2470	2018
Sun X, Xu C, Xiao G, Meng J, Wang J, Tang SC, Qin S, Du N, Li G, Ren H, Liu D, Breast cancer stem-like cells are sensitized to tamoxifen induction of self-renewal inhibition with enforced Let-7c dependent on Wnt blocking. International journal of molecular medicine, 2018 Apr;41(4):1967-1975	2018
Xiao G, Li X, Li G, Zhang B, Xu C, Qin S, Du N, Wang J, Tang SC, Zhang J, Ren H, Chen K, Sun X, MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells. Oncotarget, 2017 Nov 28;8(61):103261-103273	2017
Xiao G, Meng J, Zhang J, Li G, Du N, Qin S, Wang J, Xu C, Ren H, Tang SC, Sun X, Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers. Cancer investigation, 2017 Nov 26;35(10):639-646	2017
Wang J, Zhang B, Meng J, Xiao G, Li X, Li G, Qin S, Du N, Zhang J, Zhang J, Xu C, Tang SC, Liang R, Ren H, Sun X, Analysis of risk factors for post-operative complications and prognostic predictors of disease recurrence following definitive treatment of patients with esophageal cancer from two medical centers in Northwest China. Experimental and therapeutic medicine, 2017 Sep;14(3):2584-2594	2017
Zhang Y, Wu Z, Liu D, Wang M, Xiao G, Wang P, Sun X, Ren H, Tang SC, Du N, Augmented expression of polo-like kinase 1 indicates poor clinical outcome for breast patients: a systematic review and meta-analysis. Oncotarget, 2017 Aug 22;8(34):57723-57732	2017
Pang Y, Liu J, Li X, Zhang Y, Zhang B, Zhang J, Du N, Xu C, Liang R, Ren H, Tang SC, Sun X, Nano Let‑7b sensitization of eliminating esophageal cancer stem‑like cells is dependent on blockade of Wnt activation of symmetric division. International journal of oncology, 2017 Oct;51(4):1077-1088	2017
Chand AR, Ziauddin MF, Tang SC, Can Locoregionally Recurrent Breast Cancer Be Cured? Clinical breast cancer, 2017 Aug;17(5):326-335	2017
Noonepalle SK, Gu F, Lee EJ, Choi JH, Han Q, Kim J, Ouzounova M, Shull AY, Pei L, Hsu PY, Kolhe R, Shi F, Choi J, Chiou K, Huang TH, Korkaya H, Deng L, Xin HB, Huang S, Thangaraju M, Sreekumar A, Ambs S, Tang SC, Munn DH, Shi H, Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. Cancer immunology research, 2017 Apr;5(4):330-344	2017
Spellman A, Tang SC, Immunotherapy for breast cancer: past, present, and future. Cancer metastasis reviews, 2016 Dec;35(4):525-546	2016
Xie X, Tang SC, Cai Y, Pi W, Deng L, Wu G, Chavanieu A, Teng Y, Suppression of breast cancer metastasis through the inactivation of ADP-ribosylation factor 1. Oncotarget, 2016 Sep 6;7(36):58111-58120	2016
Kong H, Tang SC, Chemotherapy for Breast Cancer During Pregnancy, With Neonatal Lupus in the Newborn. Oncology (Williston Park, N.Y.), 2016 Jun;30(6):584-7	2016
Sun ZZ, Zhang T, Ning K, Zhu R, Liu F, Tang SC, Jiang B, Hua D, B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. Oncology reports, 2016 Jul;36(1):231-8	2016
Sun X, Liu J, Xu C, Tang SC, Ren H, The insights of Let-7 miRNAs in oncogenesis and stem cell potency. Journal of cellular and molecular medicine, 2016 Sep;20(9):1779-88	2016
Sun X, Jiang S, Liu J, Wang H, Zhang Y, Tang SC, Wang J, Du N, Xu C, Wang C, Qin S, Zhang J, Liu D, Zhang Y, Li X, Wang J, Dong J, Wang X, Xu S, Tao Z, Xu F, Zhou J, Wang T, Ren H, MiR-208a stimulates the cocktail of SOX2 and β-catenin to inhibit the let-7 induction of self-renewal repression of breast cancer stem cells and formed miR208a/let-7 feedback loop via LIN28 and DICER1. Oncotarget, 2015 Oct 20;6(32):32944-54	2015
Sun X, Tang SC, Xu C, Wang C, Qin S, Du N, Liu J, Zhang Y, Li X, Luo G, Zhou J, Xu F, Ren H, DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. Journal of cellular and molecular medicine, 2015 Jun;19(6):1357-65	2015
Gao X, Jiang B, Zou S, Zhang T, Qi X, Jin L, Ge X, Tang SC, Hua D, Chen W, Zoledronate can promote apoptosis and inhibit the proliferation of colorectal cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015 Jul;36(7):5315-22	2015
Qin S, Xu C, Li S, Yang C, Sun X, Wang X, Tang SC, Ren H, Indomethacin induces apoptosis in the EC109 esophageal cancer cell line by releasing second mitochondria-derived activator of caspase and activating caspase-3. Molecular medicine reports, 2015 Jun;11(6):4694-700	2015
Wang T, Li YQ, Liu H, Fu XL, Tang SC, Bifocal juvenile papillomatosis as a marker of breast cancer: A case report and review of the literature. Oncology letters, 2014 Dec;8(6):2587-2590	2014
Ziauddin MF, Hua D, Tang SC, Emerging strategies to overcome resistance to endocrine therapy for breast cancer. Cancer metastasis reviews, 2014 Sep;33(2-3):791-807	2014
Wang H, Du YC, Zhou XJ, Liu H, Tang SC, The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy. Cancer metastasis reviews, 2014 Mar;33(1):173-81	2014
Maegawa RO, Tang SC, Triple-negative breast cancer: unique biology and its management. Cancer investigation, 2010 Oct;28(8):878-83	2010
Liu H, Liang Y, Li Y, Li Y, Wang J, Wu H, Wang Y, Tang SC, Chen J, Zhou Q, Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer biology & therapy, 2010 May 15;9(10):832-40	2010
Tang SC, Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions. Cancer investigation, 2009 Jun;27(5):489-95	2009
Tang SC, Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer. Cancer investigation, 2009 Feb;27(2):206-14	2009
Tang SC, Predictive markers of tubulin-targeting agents in breast cancer. Clinical breast cancer, 2008 Mar;8 Suppl 2:S79-84	2008
Tang SC, Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials? Cancer investigation, 2008 Jun;26(5):481-90	2008
Ma W, Chen J, Xue X, Wang Z, Liu H, Wang T, Bai Y, Tang SC, Zhou Q, Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing. Biochemical and biophysical research communications, 2008 Jul 4;371(3):425-30	2008
Yang L, McBurney D, Tang SC, Carlson SG, Horton WE Jr, A novel role for Bcl-2 associated-athanogene-1 (Bag-1) in regulation of the endoplasmic reticulum stress response in mammalian chondrocytes. Journal of cellular biochemistry, 2007 Oct 15;102(3):786-800	2007
Hallock S, Tang SC, Buja LM, Trump BF, Liepins A, Weerasinghe P, Aurintricarboxylic acid inhibits protein synthesis independent, sanguinarine-induced apoptosis and oncosis. Toxicologic pathology, 2007 Feb;35(2):300-9	2007
Weerasinghe P, Hallock S, Tang SC, Trump B, Liepins A, Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2006 Aug;58(1):21-30	2006
Tang SC, Targeted therapy in non-small cell lung cancer. Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2004 Aug 20;7(4):284-9	2004
Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P, Khalifa M, BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast cancer research and treatment, 2004 Apr;84(3):203-13	2004
Xiong J, Chen J, Chernenko G, Beck J, Liu H, Pater A, Tang SC, Antisense BAG-1 sensitizes HeLa cells to apoptosis by multiple pathways. Biochemical and biophysical research communications, 2003 Dec 19;312(3):585-91	2003
Chen J, Xiong J, Liu H, Chernenko G, Tang SC, Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line. Oncogene, 2002 Oct 10;21(46):7050-9	2002
Tang SC, BAG-1, an anti-apoptotic tumour marker. IUBMB life, 2002 Feb;53(2):99-105	2002
Ding Z, Tang SC, Weerasinghe P, Yang X, Pater A, Liepins A, The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochemical pharmacology, 2002 Apr 15;63(8):1415-21	2002
Ding Z, Green AG, Yang X, Chernenko G, Tang SC, Pater A, Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/multidrug-resistance model. Experimental cell research, 2002 Jan 15;272(2):185-91	2002
Liang R, Li Y, Wang M, Tang SC, Xiao G, Sun X, Li G, Du N, Liu D, Ren H, MiR-146a promotes the asymmetric division and inhibits the self-renewal ability of breast cancer stem-like cells via indirect upregulation of Let-7. Cell cycle (Georgetown, Tex.), 2018;17(12):1445-1456
Xiao G, Zhang B, Meng J, Wang J, Xu C, Tang SC, Li X, Zhang J, Liang R, Ren H, Sun X, miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells. Cell cycle (Georgetown, Tex.), 2017;16(24):2374-2385
Rimando J, Campbell J, Kim JH, Tang SC, Kim S, The Pretreatment Neutrophil/Lymphocyte Ratio Is Associated with All-Cause Mortality in Black and White Patients with Non-metastatic Breast Cancer. Frontiers in oncology, 2016;6:81
Zhao Q, Xu S, Liu J, Li Y, Fan Y, Shi T, Wei S, Tang SC, Liu H, Chen J, Thyroid transcription factor-1 expression is significantly associated with mutations in exon 21 of the epidermal growth factor receptor gene in Chinese patients with lung adenocarcinoma. OncoTargets and therapy, 2015;8:2469-78
Liu H, Lu S, Gu L, Gao Y, Wang T, Zhao J, Rao J, Chen J, Hao X, Tang SC, Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2014;33(2):365-74
Liu H, Li Y, Li Y, Liu B, Wu H, Wang J, Wang Y, Wang M, Tang SC, Zhou Q, Chen J, Cloning and functional analysis of FLJ20420: a novel transcription factor for the BAG-1 promoter. PloS one, 2012;7(5):e34832
Wang T, Liu H, Chen KX, Xun P, Li HX, Tang SC, The risk factors and prognosis of bilateral primary breast cancer: a comparative study with unilateral breast cancer. Oncology research, 2011;19(3-4):171-8
Yang J, Liu H, Lu S, Gao M, Du Q, Tang SC, Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects. Oncology research, 2011;19(12):519-25
Tang SC, Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology, 2010;79(1-2):13-26
Abstracts
Chen J, Liu H, Xiong J, Kong D, Tang S-C FLJ2040: A Novel Up-regulated BAG-1 Expression Gene Proc Am Assoc Can Res. 45:1009, 2004	2004
Tang S-C, Yang J, Huang Q Differential Anti-apoptotic Functions of BAG-1 Isoforms in Breast Cancer Cells in Presence of Estrogen and Anti-estrogen Proc Am Assoc Can Res, p.1010, 2004	2004
Tang S-C, Robb J, Daniel PS Prognostic Significance of Apoptosis Proteins in Local-Regional Recurrence of Breast Cancer Proc Am Soc Clin Oncol, 22:866, 2003	2003
Doliny P, Velez P, Jorda M, Powell J, Reis I, Tang S-C, Shonukan O, Hurley J Weekly Carboplatin and Docetaxel as Neoadjuvant Therapy in Locally Advanced and Inflammatory Breast Cancers that Do Not Express HER-2 Proc Am Soc Clin Oncol, 22:63, 2003	2003
DeZarraga FI, Doliny P, Reis I, Powell J, Velez P, Gomez C, Tang S-C, Hurley J Cardiotoxicity of Neoadjuvant Trastuzumab, Docetaxel and Cisplatin is Related to BMI Proc Am Soc Clin Oncol, 22:57, 2003	2003
Tang S-C, Beck J, Chernenko G, Robb D Sensitization to Apoptosis by BAG-1 Antisense DNA is Through Modulation of BCL-2 Apoptotic Protein Family Proc Am Assoc Can Res. 43:883, 2002	2002
Tang S-C, Beck J, Chernenko G, Murphy S, Robb D, Watson P, Khalifa M Expression of BAG-1 Correlates with BCL-2, p53, Differentiation, Estrogen and Progesterone Receptor in Invasive Breast Carcinoma Proc Am Assoc Can Res. 43:45, 2002	2002
Mackey JR, Paterson A, Dirix LY, Dewar J, Chap L, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Efremedis A, Appia F, Brunel E, Hatteville L, Azli N, Nabholtz JM Final Results of the Phase III Randomized Trial Comparing Docetaxel (T), Doxorubicin (A) and Cyclophosphamide (C) to FAC as First Line Chemotherapy (CT) for Patients (pts) with Metastatic Breast Cancer (MBC) Proc Am Soc Clin Oncol, 21:35a, 2002	2002
Tang S-C, Chen J, Xiong J, Chernenko G BAG-1 Isoforms have Different Anti-apoptotic Functions Proc Am Soc Clin Oncol, 21:291b, 2002	2002
Nabholtz JA, Paterson A, Dirix L, Dewear J, Chap L, Martin M, Chan S, Tang S-C, Dugan W, Gil M, Zaluski J, Russel C, Vogel C, Borg-Olivier O, Riva A, Murawsky M, Azli N, Efremidis A A Phase III Randomized Trial Comparing Docetaxel (T), Doxorubicin (A) and Cyclophosphamide (C) (TAC) to FAC as First Line Chemotherapy (CT) for Patients (Pts) with Metastatic Breast Cancer (MBC) Proc Am Soc Clin Oncol, 20:22a, 2001	2001
Ding Z, Yang X, Pater A, Tang S-C Multidrug Resistance in Human Cervical Cells is Associated with Enhanced Expression of Anti-apoptotic Proteins BAG-1 and BCL-XL and Reduced Caspase-3 Activity Proc Am Assoc Can Res. 41:404, 2000	2000
Rorke S, Murphy S, Khalifa M, Chernenko G, Tang S-C Prognostic Significance of BAG-1 Expression in Non-Small Cell Lung Cancer (NSCLC) Proc Am Soc Clin Oncol, 19:499a, 2000	2000
Witcher M, Yang X, Pater A, Tang S-C Interaction of BAG-1p50 with the Vitamin D Receptor Suppresses Vitamin D-mediated Inhibition of Proliferation Proc Am Assoc Can Res. 40:638, 1999	1999
Tang S-C, Shahata N, Chernenko G, Pater A, Khalifa M Association of BAG-1 with Poor Survival in Breast Cancer Patients Proc Am Soc Clin Oncol. 18:609a, 1999.	1999
Quirt I, Kovacs M, Burdette-Radoux S, Dolan S, McKenzie M, Tang S-C Epoetin Alfa Reduces Transfusion Requirements, Increases Hemoglobin (Hb) and Improves Quality of Life (QofL) in Cancer Patients with Anemia who are Not Receiving Concomitant Chemotherapy Proc Am Soc Clin Oncol, 18:594a, 1999	1999
Yang X, Chernenko G, Hao Y, Ding Z, Pater MM, Pater A, Tang S-C Human BAG-1/RAP46 is Generated as Three Isoforms by Alternative Translation Initiation and Overexpressed in Human Cancer Cells Proc Am Assoc Can Res. 39:574, 1998	1998
Witcher M, Yang X, Pater A, Tang S-C A Novel Vitamin D Receptor Binding Protein Proc Am Assoc Can Res. 39:449, 1998.	1998
Yang X, Kumar KU, Pater MM, Pater A, Tang S-C Cloning and Characterization of Human BAG-1, a Protein Interacting with BCL-2 Proceedings of American Association for Cancer Research, 38:135, 1997	1997
Book Chapter
Tang S-C, Younus J, Champion P, LeBerge F, Wasil T, Mihalcioiu C Open Label, Phase II Multicenter Study of Taxotere, Adriamycin, Cyclophosphamide (TAC) Combination Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer Lung Cancer, Current Topics, Monduzzi Editor, 219-225, 2001	2001
Book
Leung WC, Jing GZ, Hasnain SE, Tang S-C, Leung M A Direct Cloning Expression System for Neutralization Antigens of Herpes Simplex Virus Modern Approaches in Vaccines (Eds. Chanock RM, Lerner RA). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, p. 179, 1984	1984
Clinical Trial
Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, McKenzie M, Couture F, Epoetin alfa in patients not on chemotherapy - Canadian data. Seminars in oncology, 2002 Jun;29(3 Suppl 8):75-80	2002

Presentations

National and International Invited Seminars/Lectures, Personalized medicine in breast cancer, University of Arizona Cancer Center, Tucson, AZ	04/2017
Regional Invited Seminars/Lectures, Precision medicine in breast cancer, fiction or reality?, Cornell University, New York City, NY	04/2017
Regional Invited Seminars/Lectures, Personalized medicine in breast cancer, University of Missouri, Columbia, MO	03/2017
Regional Invited Seminars/Lectures, Precision medicine in breast cancer, fiction or reality?, USA Mitchel Cancer Institute, University of South Alabama, Mobile, AL, Mobile, AL	03/2017
Poster Presentation, A Phase II study of ANG1005, A Novel Brain-Penetrant Taxane Derivative, for the Treatment of Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer, European Association of Neuro-Oncology, Mannheim, Germany	10/2016
Oral Presentation, ANG1005, A Novel Peptide-paclitaxel Conjugate, Crosses the BBB and Shows Activity in Patients with Recurrent CNS Metastasis from Breast Cancer: Results from a Phase II Clinical Study, European Society for Medical Oncology, Copenhagen, Denmark	10/2016
Poster Presentation, Impact of Health Disparities on Outcomes: Do Black Women with Inflammatory Breast Cancer Require Individualized Treatment Intensification?, American Society of Clinical Oncology (ASCO) Annual Meeting Abstracts, Augusta, GA	09/2016
Poster Presentation, Immune Checkpoint Inhibitors (ICI): A Meta-analysis of Immune-related Adverse Events (irAE) from Cancer Clinical Trials, American Society of Clinical Oncology Annual Meeting Abstracts, Augusta, GA	09/2016
Poster Presentation, A Meta-analysis of Immune-related Adverse Events (irAE) of Immune Checkpoint Inhibitors (ICI) from Cancer Clinical Trials, American Society of Clinical Oncology, Chicago, IL	06/2016
Oral Poster Presentation, ANG1005, A Novel Brain-Penetrant Taxane Derivative, for the Treatment of Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer, American Society of Clinical Oncology (ASCO), Chicago, IL	06/2016
Poster Presentation, A Phase II, Open-Label, Multi-Center Study of ANG1005, A Novel Brain-penetrant Taxane Derivative, in Breast Cancer Patients with Recurrent CNS Metastases, San Antonio Breast Cancer Symposium, San Antonio, TX	12/2015
Poster Presentation, A Phase 2, Randomized Trial of the IDO Pathway Inhibitor Indoximod in Combination with Taxane Based Chemotherapy for Metastatic Breast Cancer: Preliminary Data, San Antonio Breast Cancer Symposium, San Antonio, TX	12/2015
Poster Presentation, A Phase II Study of ANG1005, A Novel BBB/BCB Penetrant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer, Society of Neuro-Oncology Annual Meeting, San Antonio, TX	11/2015
National and International Invited Seminars/Lectures, Personalized precision therapy in oncology, World Cancer Conference, Dubai, United Arab Emirates	2015
Regional Invited Seminars/Lectures, San Antonio Breast Cancer Conference Update, Augusta, GA	2015
National and International Invited Seminars/Lectures, Precision Medicine in Cancer, Current approach and future direction, Chinese Academy of Engineering, Changsha, China	2015
National and International Invited Seminars/Lectures, Targeted therapy in breast cancer, Dubai, UAE	2015
National and International Invited Seminars/Lectures, Personalized medicine in breast cancer, fiction or reality?, Changsha, China	2015
National and International Invited Seminars/Lectures, The future of cancer treatment, World Forum of Academicians and University Presidents, Xuzhou, China	2014
National and International Invited Seminars/Lectures, Clinical Trial Methodologies in Oncology, Annual Chinese Radiation Oncology Conference, Chengdu, China	2014
National and International Invited Seminars/Lectures, Breast Cancer in 2014, the future is here., PCS Global Cancer Conference, Athens, Greece	2014
State/Local Invited Seminars/Lectures, Overcoming resistance in HERZ-targeted therapy, GRU Cancer Center Research in Progress Seminars	2014
National and International Invited Seminars/Lectures, Breast Cancer Therapy in 2014, Athens, Greece	2014
National and International Invited Seminars/Lectures, Clinical Management of Advanced NSCLC, Satellite Symposium of the First Latin America Lung Cancer Conference, Guarujá City, Brazil	2014
National and International Invited Seminars/Lectures, Breast Cancer Treatment, past, present and future, Sichuan Provincial Tumor Hospital, Chengdu, Sichuan, China	2013
Regional Invited Seminars/Lectures, Highlights from 2012 San Antonio Breast Cancer Conference, Southdale Medical Center, Minneapolis, MN	03/2012
National and International Invited Seminars/Lectures, San Antonio Breast Cancer Update, United Hospital Breast Cancer Tumor Board, Minneapolis, MN	01/2012
National and International Invited Seminars/Lectures, Taxanes in breast cancer, past, present and future, Regional Cancer Conference, Shantou, Fujian, China	2012
National and International Invited Seminars/Lectures, Breast Cancer in 2012, Western and Chinese Hospital, Taiyuan, China	2012
National and International Invited Seminars/Lectures, Current progress in breast cancer, Peace Hospital, Shijiazhuang, China	2012
National and International Invited Seminars/Lectures, Triple negative breast cancer, VPCI, Minneapolis, MN	10/2011
National and International Invited Seminars/Lectures, Challenge of TNB, Update on Hematology and Oncology, Minneapolis, MN	09/2011
National and International Invited Seminars/Lectures, SABCC review, VPCI, Minneapolis, MN	01/2011
National and International Invited Seminars/Lectures, Bridging the gap between USA and Asia in Cancer Drug Research and Development, Global Breast Cancer Conference, Seoul, Korea	2011
National and International Invited Seminars/Lectures, Comprehensive chemotherapy in advanced breast cancer, International Breast Cancer Conference, Tianjin, China	2011
National and International Invited Seminars/Lectures, Cancer care between China and USA, Minnesota Chinese Cancer Forum, Minneapolis, MN	10/2010
National and International Invited Seminars/Lectures, Breast Cancer, recent progress and future direction, Twin City Chinese Physician Association Annual meeting, Minneapolis-St. Paul, Minnesota	09/2010
National and International Invited Seminars/Lectures, Predictive and prognostic factors in breast cancer, Breast Cancer Update, Minneapolis, MN	08/2010
National and International Invited Seminars/Lectures, Challenging cases in metastatic breast cancer. Grand Rounds, John, B Amos Cancer Center, Columbus, GA	2010
National and International Invited Seminars/Lectures, Prognostic and predictive markers in breast cancer. Update on Breast Cancer, Minneapolis, MN	2010
National and International Invited Seminars/Lectures, ASCO update, 2010, Tianjin Tumor Institute and hospital, Tianjin, China	2010
National and International Invited Seminars/Lectures, PARP inhibitors in breast cancer, Minneapolis, MN, VPCI breast journal club	2010
National and International Invited Seminars/Lectures, Taxanes in breast cancer, VPCI breast journal club, Minneapolis, MN	2010
National and International Invited Seminars/Lectures, Global collaboration in clinical trials, 2nd USCACA Annual Meeting, Chicago, USA, June	2010
National and International Invited Seminars/Lectures, Targeted therapy in breast cancer, 4th Asia International Breast Cancer Summit, Xian, China	2010
National and International Invited Seminars/Lectures, Breast Cancer: Recent development and future direction, 4th Asia International Breast Cancer Summit, Xian, China	2010
National and International Invited Seminars/Lectures, 2008 SABCC update, Tumor Board. City of Hope Pasadena Clinic, Pasadena, CA	2009
National and International Invited Seminars/Lectures, Optimizing hormonal therapy in early breast cancer, Tumor Board. Sutter Cancer Center, Sacramento. CA	2009
Regional Invited Seminars/Lectures, Adjuvant hormonal therapy for early breast cancer, Grand Round. Marian Medical Center, Santa Maria, CA	2009
National and International Invited Seminars/Lectures, Grand Rounds. Adjuvant hormonal therapy for early breast cancer, Marian Medical Center, Santa Maria, CA	2009
National and International Invited Seminars/Lectures, Fellows Teaching Rounds: Update in hormonal therapy of early breast cancer, Ellis Fischel Cancer Center, University of Missouri in Columbia, Columbia, MO	2009
National and International Invited Seminars/Lectures, Grand Rounds: Adjuvant therapy in early breast cancer, Madrona Medical Center, Bellingham, WA	2009
National and International Invited Seminars/Lectures, Tumor Board: Current hormonal therapy in early breast cancer, St. Joseph Regional Cancer Center, Lewiston, ID	2009
National and International Invited Seminars/Lectures, Adjuvant Therapy for Early Breast Cancer. Tumor Board, Virginia G. Piper Cancer Center, Phoenix, AZ	2009
National and International Invited Seminars/Lectures, Grand Rounds. Optimizing Hormonal Therapy in Early Breast Cancer, Oklahoma University Cancer Center, Oklahoma City, OK	2009
National and International Invited Seminars/Lectures, American Society of Clinical Oncology Annual meeting Review in Breast Cancer, Central Alabama Hematology and Oncology Forum, Birmingham, AL	2009
National and International Invited Seminars/Lectures, Grand Rounds: Adjuvant therapy in early breast cancer, Madrona Medical Center, Bellingham, WA	2009
National and International Invited Seminars/Lectures, Grand Rounds. Adjuvant hormonal therapy in early breast cancer, Good Samaritan Hospital, Los Angeles, CA	2009
National and International Invited Seminars/Lectures, Tumor Board. Update in hormonal therapy of early breast cancer, Lakewood Rocky Mountain Cancer Center, Denver, CO	2009
National and International Invited Seminars/Lectures, Tumor Board. Adjuvant hormonal therapy in early breast cancer, Comprehensive Cancer Center of Nevada, Las Vegas, NV	2009
National and International Invited Seminars/Lectures, Grand Rounds. Chemotherapy in metastatic breast cancer, an update, Fairview Redwing Medical Center, Redwing, MN	2009
National and International Invited Seminars/Lectures, Tumor Board. Novel taxanes in metastatic breast cancer, Trinity Cancer Center, Birmingham, AL	2009
National and International Invited Seminars/Lectures, Grand Rounds. Update in chemotherapy of metastatic breast cancer, Southern Cancer Center	2009
National and International Invited Seminars/Lectures, Grand Rounds. Chemotherapy in metastatic breast cancer, an update, Hutchinson Medical Center, Hutchinson, MN	2009
National and International Invited Seminars/Lectures, Tumor Board. Novel taxanes in metastatic breast cancer, Northfield Hospital, Northfield, MN	2009
National and International Invited Seminars/Lectures, Grand Rounds. Update in chemotherapy of metastatic breast cancer, New Ulm Medical Center, New Ulm, MN	2009
National and International Invited Seminars/Lectures, Grand Rounds. Update in chemotherapy of metastatic breast cancer, Prairie Lakes Cancer Center, Watertown, SD	2009
National and International Invited Seminars/Lectures, Grand Rounds. Chemotherapy in metastatic breast cancer, an update, Trinity Cancer Center, Minot, ND	2009
National and International Invited Seminars/Lectures, Tumor Board. Update in chemotherapy of metastatic breast cancer, Mid-Dakota Cancer Center, Bismarck, ND	2009
National and International Invited Seminars/Lectures, Grand Rounds. Chemotherapy in early breast cancer, an update, South Austin Cancer Center, Austin, TX	2009
National and International Invited Seminars/Lectures, Tumor Board. Taxanes in early breast cancer, John Peter Smith Cancer Center, Ft. Worth, TX	2009
National and International Invited Seminars/Lectures, Grand Rounds. Update in chemotherapy of early breast cancer., The center for cancer and blood disorders, Ft. Worth, TX	2009
National and International Invited Seminars/Lectures, Tumor Board. Update in chemotherapy of early breast cancer, Stony Brook University Hospital, Stony Brook, NY	2009
National and International Invited Seminars/Lectures, Grand Rounds. Taxanes in early breast cancer, Alamance Regional Cancer Center, Burlington, NC	2009
National and International Invited Seminars/Lectures, Tumor Board. Update in early breast cancer chemotherapy, John Peter Smith Cancer Center, University of New Mexico Cancer Treatment South, Las Cruses, NM	2009
National and International Invited Seminars/Lectures, Tumor Board. Taxanes in early breast cancer., John Peter Smith Cancer Center., Ft. Worth, TX	2009
National and International Invited Seminars/Lectures, Grand Rounds. Current chemotherapy in early breast cancer, Roswell Regional Hospital, Roswell, NM	2009
National and International Invited Seminars/Lectures, Tumor Board. Taxanes in early breast cancer, Medical College of Wisconsin, Milwaukee, WI	2009
National and International Invited Seminars/Lectures, Tumor Board. Taxanes in early breast cancer, Racine, WI, Wheaton Franciscan Health Care	2009
National and International Invited Seminars/Lectures, Grand Rounds. Current chemotherapy in early breast cancer, Columbia St. Marys Cancer Center, Milwaukee, WI	2009
National and International Invited Seminars/Lectures, Update in chemotherapy of early breast cancer, Tianjin Medical University Cancer Institute and hospital, Tianjin, China	2009
National and International Invited Seminars/Lectures, Current approach in hormonal therapy in early breast cancer, Xiamen, Fujian, China	2009
National and International Invited Seminars/Lectures, Angiogenesis inhibitors in breast cancer, Shenzhen, China	2009
National and International Invited Seminars/Lectures, Highlights in breast cancer from ASCO 2009, Chinese Southwest Oncology Group Annual Meeting, Dongguan, Guangdong, China	2009
National and International Invited Seminars/Lectures, Challenges in chemotherapy of early breast cancer, Regional Breast Cancer Conference, Guilin, Guangxi, China	2009
National and International Invited Seminars/Lectures, Unique opportunity in collaboration between USA and China on cancer clinical trials, US Chinese American Anti-cancer Association Launch Meeting, Denver, CO, USA	2009
National and International Invited Seminars/Lectures, Global collaboration on clinical trials in breast cancer, 3rd Asia International Breast Cancer Summit, Chengdu, China	2009
National and International Invited Seminars/Lectures, Predictive markers of taxane response in breast cancer, 3rd Asia International Breast Cancer Summit, Chengdu, China	2009
National and International Invited Seminars/Lectures, Novel taxanes e in breast cancer, 3rd Asia International Breast Cancer Summit, Chengdu, China	2009
National and International Invited Seminars/Lectures, Overcoming Trastuzumab resistance in breast cancer, 3rd Asia International Breast Cancer Summit, Chengdu, China	2009
National and International Invited Seminars/Lectures, Current approaches in hormonal management of early breast cancer, 7th Global Breast Cancer Conference, Seoul, Korea	2009
National and International Invited Seminars/Lectures, Update in hormonal management of early breast cancer, Tumor Board, ION Group, Albuquerque, NM	2008
National and International Invited Seminars/Lectures, Grand Rounds, Current approaches in hormonal therapy in early breast cancer., Cancer Care Center of the Rockies, Ft. Collins, CO	2008
National and International Invited Seminars/Lectures, Optimal hormonal therapy in early breast cancer, University of Colorado Denver Health, Denver, CO	2008
National and International Invited Seminars/Lectures, Update in hormonal management of early breast cancer., Tumor Board. Sutter Cancer Center, Sacramento, CA	2008
National and International Invited Seminars/Lectures, Current approaches in hormonal therapy in early breast cancer., Grand Round. Memorial Hospital, Colorado Springs, CO	2008
National and International Invited Seminars/Lectures, Current approaches in hormonal therapy in early breast cancer, Grand Rounds. Nebraska Cancer Center, Lincoln, NB	2008
National and International Invited Seminars/Lectures, Tumor board: Christian Northeast Hospital. Hormonal management of early breast cancer, SABCC 2007 update, St. Louis, MO	2008
National and International Invited Seminars/Lectures, Grand Rounds: Current approaches in hormonal therapy in early breast cancer, St. Marks Hospital, Salt Lake City, UT	2008
National and International Invited Seminars/Lectures, Optimizing hormonal therapy in early breast cancer, University of New Mexico, Albuquerque, NM	2008
National and International Invited Seminars/Lectures, Challenging cases in breast cancer hormonal therapy, IX International Aromatase Conference, Shanghai, China	2008
National and International Invited Seminars/Lectures, Recent advances in the adjuvant treatment of early breast cancer, 8th Chinese Breast Cancer Conference, Chongqing, China	2008
National and International Invited Seminars/Lectures, Biomarkers of resistance to tubulin-targeting agents, Annual Taiwanese Oncology Meeting, Taipei	2008
National and International Invited Seminars/Lectures, Current clinical trials in North America, The Global Surgical Meeting, Hangzhou, China	2008
National and International Invited Seminars/Lectures, Advances in the treatment of refractory metastatic breast cancer., 10th Annual Lynn Sage Breast Cancer Symposium, Chicago	2008
National and International Invited Seminars/Lectures, Current Approached in the Hormonal Management of Early Breast Cancer, Grand Round, University of Colorado Cancer Center, Denver, CO	2007
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Management of Early Breast Cancer, Grand Round, Dartmouth University Norris Cotton Cancer Center, Lebanon, NH	2007
National and International Invited Seminars/Lectures, San Antonio Breast Cancer Conference Update, Pacific Oncology Annual Oncology Conference, Portland, OR	2007
National and International Invited Seminars/Lectures, San Antonio Breast Cancer Conference Update, Fellows Tumor Conference, University of Colorado, Denver, CO	2007
National and International Invited Seminars/Lectures, EGFR-targeted Therapy in Early Breast Cancer, Grand Round, Providence Hospital, El Paso, TX	2007
National and International Invited Seminars/Lectures, Current Approached in the Hormonal Management of Early Breast Cancer, Grand round, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA	2007
National and International Invited Seminars/Lectures, Optimal hormonal therapy for early breast cancer, First Asia Breast Cancer Summit, Beijing, China	2007
National and International Invited Seminars/Lectures, Current Approaches in the chemotherapy of early breast cancer, Sino-American Breast Conference, Xian, China	2007
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Management of Early Breast Cancer, Grand Round. University of Nebraska, Omaha, NB	2006
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Management of Early Breast Cancer, Tumor Board, UCLA, Los Angeles, CA	2006
National and International Invited Seminars/Lectures, EGFR-Targeted Therapy in MBC, Tumor Board, University of Colorado, Denver, CO	2006
National and International Invited Seminars/Lectures, Novel Taxanes in Breast Cancer, Tumor Board, University of Minnesota, MN	2006
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, Oncology Grand Round, Rush University Medical Center, Chicago, IL	2006
National and International Invited Seminars/Lectures, Chemotherapy in Lung Cancer, Oncology Grand Round, Mayo Clinic, Scottsdale, AZ	2006
National and International Invited Seminars/Lectures, Current Hormonal Management of Early Breast Cancer, Texas Oncology Nursing Society, Austin, TX	2006
National and International Invited Seminars/Lectures, Taxanes in Breast Cancer, current approach and future direction, Mexico Clinical Oncology Society Annual Meeting	2006
National and International Invited Seminars/Lectures, Locally Advanced NSCLC, the US Experience, 3rd Pan Pacific Lung Cancer Conference, Shanghai, China	2006
National and International Invited Seminars/Lectures, Current Hormonal Therapy in Early Breast Cancer, Annual Chinese Society of Clinical Oncology, Beijing, China	2006
National and International Invited Seminars/Lectures, Lung Cancer Screening, controversy and ongoing research., Mayo Clinic Medicine Forum. Scottsdale, AZ	2006
National and International Invited Seminars/Lectures, BAG-1, a Novel Anti-apoptotic Tumor Marker, Grand Round, University of Texas Southwestern Medical Center at Dallas Simmons Cancer Center, Dallas, TX	2005
National and International Invited Seminars/Lectures, BAG-1, a Novel Anti-apoptotic Tumor Marker, Grand Round, Moffitt Cancer Center, Tampa, FL	2005
National and International Invited Seminars/Lectures, Taxanes in Early Breast Cancer, Urumqi, Chengdu, Jinan and Nanjing, China	2005
National and International Invited Seminars/Lectures, BAG-1, a Novel Anti-apoptotic Tumor Marker: From Laboratory to Clinical Practice, Grand Round, University of Florida, Gainesville, FL	2005
National and International Invited Seminars/Lectures, Update in Chemotherapy in Lung Cancer, Grand Round, Nevada Cancer Institute, Las Vegas, NV	2005
National and International Invited Seminars/Lectures, Current Hormonal Management of Early Breast Cancer, Grand Round, Long Island Cancer Center, State University of New York at Stony Brook, Stony Brook, NY	2005
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Management of Early Breast Cancer, Tumor Board, University of Texas Medical Branch, Galveston, TX	2005
National and International Invited Seminars/Lectures, BAG-1, a Novel Anti-apoptotic Tumor Marker: From Laboratory to Clinical Practice, Grand Round, University of West Virginia, Charlottesville, VA	2005
National and International Invited Seminars/Lectures, Update in Chemotherapy for NSCLC, Best Practices in Oncology, Richmond, VA	2005
National and International Invited Seminars/Lectures, Current Strategy in the Hormonal Treatment of Early Breast Cancer, Taiwan Breast Cancer Society Conference, Kaohsiung, Taiwan	2005
National and International Invited Seminars/Lectures, New Direction for Breast Cancer Treatment: Increasing Efficacy and Decreasing Toxicity, KL, Malaysia	2005
National and International Invited Seminars/Lectures, Current Hormonal Management of Early Breast Cancer, Grand Round, Northridge Hospital, Northridge, CA	2005
National and International Invited Seminars/Lectures, Optimizing Hormonal Therapy in Early Breast Cancer, Annual Meeting of the Israeli Oncology Society, Eilat, Israel	2005
National and International Invited Seminars/Lectures, Targeted Therapy in Breast Cancer, XXII Joint Annual Meeting of Panamanian Oncology Society and NCI Mexico, Panama City, Panama	2005
National and International Invited Seminars/Lectures, Optimizing Chemotherapy in Early Breast Cancer, North China Breast Cancer Forum, Beijing, China	2005
National and International Invited Seminars/Lectures, Current Principles of Chemotherapy in Early and Advanced Breast Cancers, First African Oncology Conference, Nairobi, Kenya	2005
National and International Invited Seminars/Lectures, Changing Paradigm of Adjuvant Hormonal Therapy in Early Breast Cancer, First African Oncology Conference, Nairobi, Kenya	2005
National and International Invited Seminars/Lectures, Expanding Role of Bisphosphonates in Solid Tumor, 7th Chinese National Metastatic Cancer Conference, Chengdu, Sichuan, China	2005
National and International Invited Seminars/Lectures, Current Strategy in the Hormonal Treatment of Early Breast Cancer, Taiwan Breast Cancer Society Conference, Taipei, Taiwan	2005
National and International Invited Seminars/Lectures, Current Strategy in the Hormonal Treatment of Early Breast Cancer, Hong Kong Society of Clinical Oncology and Hong Kong College of Radiologists Conference, Hong Kong, China	2005
National and International Invited Seminars/Lectures, Optimizing Hormonal Therapy in Early Breast Cancer, Malaysia and Singapore Oncology Society Joint Scientific Meeting, Johor Bahru, Malaysia	2005
National and International Invited Seminars/Lectures, Hormonal Management of Early Breast Cancer: Current Data and Future Directions, Costa Rica Oncology Society Conference, San Jose, Costa Rica	2005
National and International Invited Seminars/Lectures, Aromatase Inhibitors in Breast Cancer, 3rd AFME Symposium, Istanbul, Turkey	2005
National and International Invited Seminars/Lectures, Novel Agents in Breast Cancer, 1st LACORE Summit, Iguacu, Brazil	2005
National and International Invited Seminars/Lectures, Aromatase Inhibitors in Metastatic Breast Cancer, 1st LACORE Summit, Iguacu, Brazil	2005
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Therapy in Early Breast Cancer, The BIG Caribbean Meeting, Tikal, Guatemala	2005
National and International Invited Seminars/Lectures, Current Strategy in the Hormonal Management of Early Breast Cancer, Central Latin American Oncology Forum, Santo Domingo, Dominican Republic	2005
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Therapy in Early Breast Cancer, XXII Joint Annual Meeting of Panamanian Oncology Society and NCI Mexico, Panama City, Panama	2005
National and International Invited Seminars/Lectures, Highlights from 2003 SABCC, Grand Rounds, Glendale Memorial Hospital and Health Center, CA	2004
National and International Invited Seminars/Lectures, Grand Rounds: Changing Paradigm of Adjuvant Hormonal Therapy in Early Breast Cancer, UCLA Harbor Medical Center, Los Angeles, CA	2004
National and International Invited Seminars/Lectures, Anemia in Cancer Patients, Oncology Nursing Society Florida Chapter Annual Meeting, Tampa, FL	2004
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, National Iressa Launch Meeting, Antigua Guatemala	2004
National and International Invited Seminars/Lectures, Update on Adjuvant Hormonal Therapy in Early Breast Cancer, Post-ASCO Review, Grand Round, Pocono Medical Center, Stroudsburg, PA	2004
National and International Invited Seminars/Lectures, Future Direction of Epidermal Growth Factor Inhibitors in Solid Tumor, Monterrey, Mexico	2004
National and International Invited Seminars/Lectures, Future Direction of Epidermal Growth Factor Inhibitors in Solid Tumor, National Iressa Launch Meeting, Mexico City, Mexico	2004
National and International Invited Seminars/Lectures, Update on Breast Cancer, Grand Round, NCH Health Care System, Naples, FL	2004
National and International Invited Seminars/Lectures, Update on the Adjuvant Therapy of Early Breast Cancer, Shanghai Cancer Institute, Shanghai, China	2004
National and International Invited Seminars/Lectures, Systemic Therapy in Advanced NSCLC, Guarujá City, Brazil	2004
National and International Invited Seminars/Lectures, Use of Aromatase Inhibitors in Advanced Breast Cancer, Novartis First Asia Pacific Oncology Summit, Hainan, China	2004
National and International Invited Seminars/Lectures, Current Strategy in the Adjuvant Treatment of Breast Cancer, Ormond Beach, FL	2004
National and International Invited Seminars/Lectures, Highlights from 2003 SABCC, Tumor Board, Olive View Medical Center, CA	2004
National and International Invited Seminars/Lectures, Highlights from 2003 SABCC, Grand Rounds, Cancer Center of Santa Barbara, Santa Barbara, CA	2004
National and International Invited Seminars/Lectures, Highlights from 2003 SABCC, Encino-Tarzana Regional Medical Center Grand Rounds, Burbank, CA	2004
National and International Invited Seminars/Lectures, Changing Paradigm of Hormonal Therapy in Early Breast Cancer, 8th Korean Breast Cancer Society Annual Conference, Seoul, Korea	2004
National and International Invited Seminars/Lectures, Extended Adjuvant Therapy in Early Breast Cancer, Mexico Annual Mastology Conference, Acapulco, Mexico	2004
National and International Invited Seminars/Lectures, Current Management of Advanced NSCLC, Guatemala National Oncology Conference, Guatemala City, Guatemala	2004
National and International Invited Seminars/Lectures, Angiogenesis and Apoptosis in Breast Cancer, Second Inter-American Breast Cancer Conference, Cancun, Mexico	2004
National and International Invited Seminars/Lectures, Polychemotherapy in the Adjuvant Treatment of Early Breast Cancer, 9th Annual Conference of the Association of Clinical Oncology of Taiwan, Taipei, Taiwan	2004
National and International Invited Seminars/Lectures, Changing Paradigm in the Hormonal Management of Early Breast Cancer, 7th Annual Chinese Society of Clinical Oncology Conference, Kunming, China	2004
National and International Invited Seminars/Lectures, Aromatase Inhibitors in Early Breast Cancer, Asia Breast Cancer Conference, Taipei, Taiwan	2004
National and International Invited Seminars/Lectures, Differential anti-apoptotic functions of BAG-1 isoforms in breast cancer cells in the presence of estrogen and anti-estrogen., 27th San Antonio Breast Cancer Conference	2004
National and International Invited Seminars/Lectures, FLJ2040 gene: A novel up-regulator of BAG-1 expression., American Association for Cancer Research Annual Meeting	2004
National and International Invited Seminars/Lectures, Differential anti-apoptotic functions of BAG-1 isoforms in breast cancer cells in presence of estrogen and anti-estrogen., 95th American Association for Cancer Research Annual Meeting	2004
National and International Invited Seminars/Lectures, Update on the Management of Advanced NSCLC, Arizona Clinical Oncology Society, Phoenix, AZ	2003
National and International Invited Seminars/Lectures, Current Issues and Future Direction in Clinical Oncology, University of Arizona, Tucson, AZ	2003
National and International Invited Seminars/Lectures, BAG-1, A Novel Anti-apoptotic Tumor Marker in NSCLC, University of West Virginia Annual Lung Cancer Research Meeting, Morgantown, WV	2003
National and International Invited Seminars/Lectures, Small Cell Lung Cancer Evolving Approaches, University of Florida Thoracic Oncology Update 2003 Symposium, Jacksonville, Florida	2003
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, West China University of Medical Sciences, Chengdu, China	2003
National and International Invited Seminars/Lectures, Update on the Treatment of SCLC, Joint Cancer Conference of Florida Universities, Orlando, Florida	2003
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, Latin America Oncology Conference, Curacao	2003
National and International Invited Seminars/Lectures, Platinum vs. Non-Platinum Doublets in Advanced NSCLC According to BAG-1 Expression, ECOG Lung Cancer Committee, New Orleans	2003
National and International Invited Seminars/Lectures, Open Label Phase II Trial of Targretin in Stage III NSCLC after Chemoradiation, ECOG Lung Cancer Committee, New Orleans	2003
National and International Invited Seminars/Lectures, BAG-1, an Anti-apoptotic Tumor Marker, Department of Immunology and Microbiology, University of Miami, Miami, Florida	2003
National and International Invited Seminars/Lectures, Targeted Therapy in Cancer, Clinician Scientist Course, University of Miami, Miami, Florida	2003
National and International Invited Seminars/Lectures, New Insight into the Anemia and Lung Cancer, Grand Round, VA Hospital, West Palm Beach, Florida	2003
National and International Invited Seminars/Lectures, American Society of Clinical Oncology Annual Meeting Review in Breast Cancer, Georgia Cancer Foundation, Macon, Georgia	2003
National and International Invited Seminars/Lectures, Integration of Epirubicin in the Management of Breast Cancer, NOCR Regional Advisory Board, Las Vegas, Arizona	2003
National and International Invited Seminars/Lectures, Exploring Diagnosis and Treatment of Advanced NSCLC, Stuart, Florida	2003
National and International Invited Seminars/Lectures, American Society of Clinical Oncology Annual Meeting Review in Breast Cancer, South Carolina Oncology Associate Annual Meeting, Columbia, South Carolina	2003
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, National Oncology Conference, Mexico City, Mexico	2003
National and International Invited Seminars/Lectures, New Insight into the Anemia and Breast Cancer, Grand Rounds, Baptist Hospital, Miami, FL	2003
National and International Invited Seminars/Lectures, Update on the Treatment of SCLC, Tumor Board, St. Vincent Hospital, University of Florida, Jacksonville, FL	2003
National and International Invited Seminars/Lectures, Anemia and Breast Cancer, New Data and Future Direction, Grand Round, Cedar Hospital, Miami, FL	2003
National and International Invited Seminars/Lectures, Chemotherapy in Advanced Lung and Breast Cancer, Choosing the Right Drugs, Chongqing, Hong Kong (Prince of Whales Hospital, Queen Marys Hospital and Chinese University of Hong Kong Hospital), Beijing, Xian and Jinan, China	2003
National and International Invited Seminars/Lectures, Therapeutic Options in SCLC, Seattle, WA	2003
National and International Invited Seminars/Lectures, New Chemotherapy Options in Metastatic Breast Cancer, Asian Clinical Oncology Society Annual Meeting, Seoul, Korea	2003
National and International Invited Seminars/Lectures, BAG-1 as a Novel Prognostic Tumor Marker, Latin America Oncology Conference, Curacao	2003
National and International Invited Seminars/Lectures, Current Management of NSCLC, Latin America Oncology Conference, Curacao	2003
National and International Invited Seminars/Lectures, Current Management of NSCLC, National Oncology Conference, Mexico City, Mexico	2003
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, Latin America Oncology Forum, Mexico City, Mexico	2003
National and International Invited Seminars/Lectures, Current Management of Advanced NSCLC, Argentina National Oncology Conference, Cordova, Argentina	2003
National and International Invited Seminars/Lectures, Integration of EGFRI in Oncology Practice, Current Data and Future Direction, Argentina National Oncology Conference, Cordova, Argentina	2003
National and International Invited Seminars/Lectures, Targeted Therapy in NSCLC, First West China Oncology Cooperative Group Annual Meeting, Chengdu, Sichuan, China	2003
National and International Invited Seminars/Lectures, Optimizing Adjuvant Chemotherapy in Early Breast Cancer, Asian Clinical Oncology Society Annual Meeting, Seoul, Korea	2003
National and International Invited Seminars/Lectures, Phase I clinical trial with Topotecan, Adriamycin and Vincristine (TAV) in patients with advanced small (SCLC) and non-small cell lung cancer (NSCLC)., 10th World Conference on Lung Cancer	2003
National and International Invited Seminars/Lectures, Immunotherapy with gene-modified allogenic cells successfully induced CD8 T cell and clinical responses in patients with advanced non-small cell lung cancer (NSCLC)., 10th World Conference on Lung Cancer	2003
National and International Invited Seminars/Lectures, Weekly carboplatin and docetaxel as neoadjuvant therapy in locally advanced and inflammatory breast cancers that do not express HER-2., American Society of Clinical Oncology Annual Meeting	2003
National and International Invited Seminars/Lectures, Cardiotoxicity of Neoadjuvant Trastuzumab, Docetaxel and Cisplatin as related to BMI., American Society of Clinical Oncology Annual Meeting	2003
National and International Invited Seminars/Lectures, Differential Diagnosis of Patient with Generalized Lymphadenopathy, Morbidity and Mortality Rounds, Jackson Memorial Hospital, University of Miami, Miami, Florida	2002
National and International Invited Seminars/Lectures, BAG-1, a Novel Prognostic Tumor Marker, Department of Medicine, University of Miami, Miami, Florida	2002
National and International Invited Seminars/Lectures, Morbidity and Mortality Rounds, Department of Medicine, University of Miami, Miami, Florida	2002
National and International Invited Seminars/Lectures, BAG-1, a Novel Prognostic Tumor Marker, Department of Microbiology and Immunology, University of Miami, Florida	2002
National and International Invited Seminars/Lectures, Update on Lung Cancer Biology and Treatment, Grand Round, Department of Medicine, University of Miami, Miami, Florida	2002
National and International Invited Seminars/Lectures, Current Management of NCSLC, Department of Medicine, University of Miami, Miami, Florida	2002
National and International Invited Seminars/Lectures, Predictive and Prognostic Markers in Breast Cancer, Clinical and Therapeutic Implications, Advances of Diagnosis and Treatment in Oncology, International Scientific Symposium, La Plata, Argentina	2002
National and International Invited Seminars/Lectures, Novel Therapies in NSCLC, Gene Therapy, Advances of Diagnosis and Treatment in Oncology, International Scientific Symposium, La Plata, Argentina	2002
National and International Invited Seminars/Lectures, Adjuvant Hormonal Therapy in Breast Cancer, First Inter-American Breast Cancer Conference, Cancun, Mexico	2002
National and International Invited Seminars/Lectures, Prognostic Significance of BAG-1 Expression in Breast Cancer, First Inter-American Breast Cancer Conference, Cancun, Mexico	2002
National and International Invited Seminars/Lectures, Prognostic significance of apoptosis proteins in local-regional recurrence of breast cancer, American Society of Clinical Oncology Annual Meeting	2002
National and International Invited Seminars/Lectures, Sensitization to apoptosis by antisense BAG-1 is mediated by multiple apoptotic pathways., Zubrod Memorial Lecture and Annual Poster Presentation, University of Miami Sylvester Comprehensive Cancer Center	2002
National and International Invited Seminars/Lectures, Expression of Mcl-1 predicts absence of local-regional recurrence of breast carcinoma., San Antonio Breast Cancer Symposium	2002
National and International Invited Seminars/Lectures, Expression of BAG-1 correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptor in invasive breast carcinoma., 93rd American Association for Cancer Research Annual Meeting	2002
National and International Invited Seminars/Lectures, Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)., American Society of Clinical Oncology Annual Meeting	2002
National and International Invited Seminars/Lectures, Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)., American Society of Clinical Oncology Annual Meeting	2002
National and International Invited Seminars/Lectures, BAG-1 isoforms have different anti-apoptotic functions., American Society of Clinical Oncology Annual Meeting	2002
National and International Invited Seminars/Lectures, Expression of BAG-1 correlates with p53, Bcl-2, differentiation, estrogen receptor and progesterone receptor in invasive breast cancer., Expression of BAG-1 correlates with p53	2002
National and International Invited Seminars/Lectures, BAG-1, a Novel Tumor Marker, Sylvester Comprehensive Cancer Center Miami, Florida	09/2001
National and International Invited Seminars/Lectures, New Hormonal Therapy for Breast Cancer, Xian, China	09/2001
National and International Invited Seminars/Lectures, Open Label, Phase II Multicentre Study of Taxotere, Adriamycin, Cyclophosphamide (TAC) Combination Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer, 7th Central European Lung Cancer Conference, Prague, Czech Republic	06/2001
National and International Invited Seminars/Lectures, Hope and Challenge of Breast Cancer Care in the New Millennium, 2nd Breast Cancer Survivor Retreat, Gros Morne, Newfoundland	05/2001
National and International Invited Seminars/Lectures, Emerging Role of Letrozole in Metastatic Breast Cancer, Atlantic Canada Oncology Group 5th Annual Winter Symposium, Corner Brook, Newfoundland	02/2001
National and International Invited Seminars/Lectures, Adding Xeloda (X, Capecitabine) to Docetaxel (D) significantly improves survival and does not compromise QoL in patients with MBC., San Antonio Breast Cancer Symposium	2001
National and International Invited Seminars/Lectures, A phase III randomized trial comparing Docetaxel (T), Doxorubicin (A) and Cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)., American Society of Clinical Oncology Annual Meeting	2001
National and International Invited Seminars/Lectures, BAG-1, A Novel Antiapoptotic Prognostic Tumor Marker, Moffitt Cancer Center, Tampa, Florida	10/2000
National and International Invited Seminars/Lectures, A Novel Prognostic Factor in Non-Small Cell Lung Cancer, 5th World Congress on Advances in Oncology and 3rd International Symposium on Molecular Medicine, Greece	10/2000
National and International Invited Seminars/Lectures, BAG-1, A Novel Anti Apoptotic Prognostic Tumor Marker, Ottawa Cancer Center, Ottawa	09/2000
National and International Invited Seminars/Lectures, Prognostic Significance of BAG-1 Expression in Non-Small Cell Lung Cancer, 9th World Conference on Lung Cancer, Tokyo, Japan	09/2000
National and International Invited Seminars/Lectures, Challenges of Clinical Trials in a Small Academic Center, Thunder Bay, Thunder Bay	05/2000
National and International Invited Seminars/Lectures, Small Cell Lung Cancer: The Promise of the New Drugs, 4th Atlantic Canada Oncology Group Annual Symposium, Corner Brook, Newfoundland	02/2000
National and International Invited Seminars/Lectures, Multidrug resistance in human cervical cells is associated with enhanced expression of anti-apoptotic proteins BAG-1 and BCL-XL and reduced Caspase-3 activity., American Association for Cancer Research 91st Annual Meeting	2000
National and International Invited Seminars/Lectures, Prognostic significance of BAG-1 expression in non-small-cell lung cancer (NSCLC)., American Society of Clinical Oncology Annual Meeting	2000
National and International Invited Seminars/Lectures, Prognostic value of BAG-1 in NSCLC, Canadian Association of Medical Oncologists Annual Meeting	2000
National and International Invited Seminars/Lectures, BAG-1, A Novel Prognostic Marker for Breast Cancer, Breast Cancer Research, Reasons for Hope: NCIC National Scientific Conference, Toronto	06/1999
National and International Invited Seminars/Lectures, Eprex in Anemic Cancer Patients, Atlantic Experience, Cancer Care Nova Scotia, Halifax	06/1999
National and International Invited Seminars/Lectures, Herceptin, the Great Canadian Debate Panelist, NCIC Satellite Symposium	04/1999
Poster Presentation, BAG-1 is Generated as Four Isoforms by Alternative Translation Initiation and is Over-expressed in Cervical Cancer Cell, Proceedings of 17th International Papillomavirus Conference, Charleston, South Carolina	01/1999
National and International Invited Seminars/Lectures, Small Cell Lung Cancer, the Promise of New Drugs, Chinese Lung Cancer Symposium, Chengdu, China	1999
National and International Invited Seminars/Lectures, BAG-1 is generated as four isoforms by alternative translation initiation and is over-expressed in cervical cancer cell., 17th International Papillomavirus Conference	1999
National and International Invited Seminars/Lectures, Multidrug resistance in human cervical cells is associated with enhanced expression of anti-apoptotic proteins BAG-1 and BCL-XL and reduced caspase-3 activity, AACR 91st Annual Meeting	1999
National and International Invited Seminars/Lectures, BAG-1, a novel prognostic marker for breast cancer., Breast Cancer Research: Reasons for Hope, National Scientific Conference	1999
National and International Invited Seminars/Lectures, Epoetin alfa reduces transfusion requirements, increase hemoglobin (Hb) and improves quality of life (QofL) in cancer patients with anemia who are not receiving concomitant chemotherapy., American Society of Clinical Oncology Annual Meeting	1999
National and International Invited Seminars/Lectures, Interaction of BAG-1p50 with the vitamin D receptor suppresses vitamin D-mediated inhibition of proliferation., American Association for Cancer Research Annual Meeting	1999
National and International Invited Seminars/Lectures, Association of BAG-1 with poor survival in breast cancer patients., American Society of Clinical Oncology Annual Meeting	1999
National and International Invited Seminars/Lectures, Expression of apoptotic-associated proteins in multi-drug resistant human cervical cells., Third Atlantic Canada Oncology Group Winter Symposium	1999
State/Local Invited Seminars/Lectures, Resistance to apoptosis induced by DNA damage during cervical Oncogenesis: Correlation with the expression of anti-apoptotic gene BAG-1., Third Atlantic Canada Oncology Group Winter Symposium	1999
State/Local Invited Seminars/Lectures, Expression of BAG-1, p53 and Bcl-2 in lung carcinoma., Third Atlantic Canada Oncology Group Winter Symposium	1999
National and International Invited Seminars/Lectures, Prognostic Value of BAG-1 in Breast Cancer, 2nd Atlantic Canada Oncology Group Annual Symposium, Corner Brook, NF, Canada	1998
National and International Invited Seminars/Lectures, Update in Breast Cancer Chemotherapy, ASCO Review, St. Johns, NF, Canada	1998
National and International Invited Seminars/Lectures, Anemia in Cancer Patients, Charlottetown, Prince Edward Island, Canada	1998
National and International Invited Seminars/Lectures, Modern Chemotherapy for Advanced NSCLC, Second Chinese Society of Clinical Oncology Satellite Symposium, Nanjing, China	1998
National and International Invited Seminars/Lectures, New Hormonal Therapies for Breast Cancer, Chengdu, Beijing, Guangzhou, Shenyang, China	1998
National and International Invited Seminars/Lectures, Induction of caspase-3-like dependent and independent bimodal apoptosis in human malignant cervical cells by the alkaloid Sanguinarine., International Business Communications Fifth Annual Conference on Apoptosis	1998
National and International Invited Seminars/Lectures, A Novel Prognostic Factor in Invasive Breast Cancer, Second Chinese Society of Clinical Oncology, Nanjing, China	1998
National and International Invited Seminars/Lectures, A novel vitamin D receptor binding protein., American Association for Cancer Research Annual Meeting	1998
National and International Invited Seminars/Lectures, Human BAG 1/RAP46 is generated as three isoforms by alternative translation initiation and is overexpressed in human cancer cells., American Association for Cancer Research Annual Meeting	1998
National and International Invited Seminars/Lectures, Distinct patterns of HPV-16 infections in native epithelium and in metaplasia., The American Society of Virology 17th Annual Meeting	1998
State/Local Invited Seminars/Lectures, Cloning of the gene encoding lymphocyte differentiation antigen CD9., New Frontiers in Cancer Research	1998
State/Local Invited Seminars/Lectures, Prognostic value of BAG-1 in invasive breast cancer: a retrospective study., Second Atlantic Canada Group Winter Symposium	1998
Poster Presentation, Distinct Patterns of HPV-16 Infections in VIN 1 in Native Epithelium and CIN 1 in Metaplasia, Proceedings of 16th International Papillomavirus Conference, Siena, Italy	09/1997
National and International Invited Seminars/Lectures, Prognostic Value of BAG-1 in Non-Small Cell Lung Cancer, Manitoba Cancer Treatment and Research Foundation	1997
National and International Invited Seminars/Lectures, Cancer Gene Therapy: Fiction or Reality, Canadian Cancer Society Annual Conference, St. John's, NF, Canada	1997
National and International Invited Seminars/Lectures, BAG-1, A New Player in Apoptosis, Ontario Cancer Treatment and Research Foundation, Sudbury, ON, Canada	1997
National and International Invited Seminars/Lectures, Update in Lung Cancer Chemotherapy, ASCO Review, St. Johns, NF, Canada	1997
National and International Invited Seminars/Lectures, Advanced NSCLC, Role of Systemic chemotherapy, 1st Atlantic Canada Oncology Group Annual Symposium, Corner Brook, NF, Canada	1997
National and International Invited Seminars/Lectures, Systemic Therapy for Advanced Non-Small Cell Lung Cancer, Ontario Cancer Treatment and Research Foundation, Sudbury, ON, Canada	1997
National and International Invited Seminars/Lectures, BAG-1, The New Player in Apoptosis, British Columbia Cancer Agency, Vancouver, BC, Canada	1997
National and International Invited Seminars/Lectures, Are There Any Useful Markers for the Prognosis of Lung Cancer?, Nova Scotia Cancer Treatment and Research Foundation, Halifax, NS, Canada	1997
National and International Invited Seminars/Lectures, New Markers for the Prognosis of Lung Cancers, University of Manitoba, Winnipeg, Manitoba	1997
National and International Invited Seminars/Lectures, Distinct patterns of HPV-16 infections in native epithelium and in metaplasia., 16th International Papillomavirus Workshop	1997
National and International Invited Seminars/Lectures, Cloning and characterization of human BAG-1, a protein interacting with Bcl-2., American Association for Cancer Research Annual Meeting	1997
State/Local Invited Seminars/Lectures, Prolonged, severe 5-fluorouracil-associated neurotoxicity in patient with dihydropyridine dehydrogenase deficiency., Royal College of Physicians and Surgeons of Canada Annual Meeting, Canada	1997
National and International Invited Seminars/Lectures, Advanced Lung Carcinoma: Who Should we Treat?, NCTRF Annual Cancer Conference, St. John's, NF, Canada	1996
National and International Invited Seminars/Lectures, Update in Lung Cancer Chemotherapy, Nova Scotia Cancer Treatment and Research Foundation, Halifax, NS, Canada	1996
Poster Presentation, Objective Clinical Responses in Patients with Progressive/Recurrent Low-Grade Lymphoma Treated with Campath-1H Monoclonal Antibody, Proceedings of Annual Meeting of American Society Clinical Oncology, Baltimore, MD	1995
National and International Invited Seminars/Lectures, Objective clinical responses in patients with progressive/recurrent low-grade lymphoma treated with Campath-1H monoclonal antibody., American Society of Clinical Oncology Annual Conference	1995
National and International Invited Seminars/Lectures, Campath-1H monoclonal antibody can induce objective clinical response in patients with recurrent low-grade lymphoma., American Society of Hematology Annual Conference	1994
State/Local Invited Seminars/Lectures, Molecular cloning of the human lymphocyte differentiation antigen CD9., Heritage Research Day	1988
State/Local Invited Seminars/Lectures, Structural relationships of the membrane glycoproteins gp22 and gp24., Third Terry Fox Cancer Research Conference	1985
Poster Presentation, A New Approach for Chemical-enzymatic Synthesis of IFN-Y Gene and Strategy of Site-specific Mutagenesis, International Congress for Virology, Sendai, Japan	09/1984
Poster Presentation, Site-specific Mutagenesis of RNA Genome, International Congress for Virology, Sendai, Japan	09/1984
National and International Invited Seminars/Lectures, Protein engineering of IFN by using novel approaches for chemical enzymatic gene synthesis and fragment replacement method for site-specific mutagenesis., Antiviral Research	1984
National and International Invited Seminars/Lectures, Site-specific mutagenesis of RNA genome., Sixth International Congress of Virology	1984
National and International Invited Seminars/Lectures, Gene synthesis, site-specific mutagenesis for protein and RNA engineering., Sixth International Congress of Virology	1984
State/Local Invited Seminars/Lectures, Site-specific mutagenesis and protein engineering of IFN., Heritage Research Day, Canada	1984
National and International Invited Seminars/Lectures, Update on chemotherapy in MBC, UCLA Santa Monica Clinic, Los Angeles, CA
National and International Invited Seminars/Lectures, Breast Cancer, current issues, University of Minnesota Radiation Oncology Fellows course, Minnesota
National and International Invited Seminars/Lectures, American Society of Clinical Oncology Annual meeting Review in Breast Cancer, Central Alabama Hematology and Oncology Forum, Birmingham, Alabama
State/Local Invited Seminars/Lectures, BAG-1 expression correlates with survival in patients with non-small cell lung carcinoma., The United States-Canadian Academy of Pathology

Teaching Experience

Medicine, Lecture, Lecturer, Clinical Trials Design

Fall 2018

Directed Student Learning

GRU Nursing Ph.D. Candidate Mentorship, Advised: Dawn L. Langley-Brady
Preceptor, Advised: Sheri Nightingale, Dianne Hemeon, Robb Brown, John Brenton, Dr. Wang Ling, Dr. Wang Zhen, Dr. Hong Ren, Dr. Shouyi Zhi, Sergio Fleites, Dr. Leilei Zhou, Dr. Dong Hua, Dr. Hou-Jie Liang
Medical Student Mentorship, Advised: Cheryl Jain
Summer Students Mentorship, Advised: Sylvia Mouland, Cheryl Power, Scott Vatcher
Honor Student Mentorship, Advised: Jessalyn Beck
Clinical Clerks Mentorship, Advised: Joy Greenland, Michelle Yang, Cindy Card

Fellows supervised

Fellows Medical Oncology, Mentorship, 7 fellows supervised
University of Newfoundland Resident Program, Resident Mentor, 4 fellows supervised
M.Sc. Internal Examiner, Post-Doc Advisor, 2 fellows supervised
Ph.D. Examination Committee, Post-Doc Advisor, 2 fellows supervised
Ph.D. Supervisory Committee, Post-Doc Advisor, 1 fellows supervised
Post-Doc Advisor, 7 fellows supervised
Post-Doc Advisor, 6 fellows supervised
Mentor, 2 fellows supervised

Intramural, Prediction of IncRNA Function Based on Large-scale Breast Cancer Expression Database, University of Mississippi Medical Center	01/2018 - 01/2019
Extramural, A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Fulvestrant in Subjects with ER+ Breast Cancer, GlaxoSmithKline	12/2016 - 04/2017
Extramural, A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer, Innocrin Pharmaceuticals, Inc.	11/2016 - 11/2017
Extramural, A Phase III Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination with Fulvestrant for Men and Postmenopausal Women with Hormone Receptor Positive, HER2-negative Advanced Breast Cancer which Progressed on or after Aromatase Inhibitor Treatment, Novartis	06/2016 - 06/2020
Extramural, 00031332 Phase 2 Randomized, Double-Blind, Controlled Study of ONT-380 vs. Placebo in Combination with Capcitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer, Cascadian	04/2016 - 04/2019
Extramural, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Non-steroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco-regionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting, Eli Lilly	01/2016 - 01/2018
Extramural, 00030996 neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy with Abemaciclib in Combination with Anastrozole in Postmenopausal Women with Hormone Receptor Positive, HER2 Negative Breast Cancer, Eli Lilly	01/2016 - 01/2018
Extramural, 00029776 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy in this Disease Setting, Eli Lilly	01/2015 - 01/2024
Extramural, A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER2+ Breast Cancer Patients with Progressive/Recurrent Brain Metastases to Investigate Role of ANG1005 in Patients with Brain Metastases, Angiochem	09/2014 - 09/2016
Extramural, EGF114299: A Phase III Trial to Compare the Safety and Efficacy of Lapatinib plus Trastuzumab plus an Aromatase Inhibitor (AI) versus Trastuzumab plus an AI versus Lapatinib plus an AI as First- or Second-line Therapy in Postmenopausal Subjects with Hormone Receptor Positive, HER2-positive Metastatic Breast Cancer (MBC) who have Received Prior Trastuzumab and Endocrine Therapies, GlaxoSmithKline	09/2014 - 09/2018
Extramural, A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ- 42756493, a Pan-fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects with Advanced or Refractory Solid Tumors or Lymphoma to Investigate the Role of JNJ- 42756493 in Solid Tumors (Active), Janssen	03/2014 - 06/2017
Intramural, Aspirin Use and PI3K Mutation in Breast Cancer, A Pilot Study, GRU Cancer Center Directors Innovation Award	01/2014 - 01/2017
Extramural, 00027816 A Phase II Study of Docetaxel in Combination with 1-Methyl-D-Tryptophan (Indoximod) in Metastatic Breast Cancer, New Link Genetics	07/2013 - 07/2016
Extramural, NLG2101: A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (Indoximod) in Metastatic Breast Cancer, NewLink Genetics Corp	03/2013 - 03/2016
Extramural, Asia International Breast Cancer Summit, Novartis, GSK, Abraxis and Merck	04/2008 - 04/2008
Extramural, Prognostic and Predictive Markers in Breast Cancer, University of Colorado Denver, Aurora, CO and Denver Health	01/2008 - 01/2012
Extramural, Susan G. Komen Grant, Denver Health, Denver, CO	01/2008 - 12/2008
Extramural, Visiting Professorship Grant, Tianjin Municipal Government and Tianjin Medical University China	01/2008 - 12/2008
Extramural, First Asia International Breast Cancer Summit, Novartis, GSK and Abraxis	03/2007 - 03/2007
Extramural, BAG-1 in Breast Cancer Prognosis and Treatment, University of Colorado Cancer Center and Denver Health Medical Center Startup Fund	01/2007 - 01/2009
Extramural, BAG-1 and EGFRs in Lung Cancer, ImClone, USA	01/2005 - 12/2005
Extramural, A Randomized, Double Blind, Multicenter Study To Compare The Efficacy and Tolerability of Fulvestrant (Faslodex) vs. Exemestane (Aromasin) in Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer with Disease Progression after Prior Non-Steroidal Aromatase Inhibitor (AI) Therapy, AstraZeneca	01/2004 - 01/2006
Extramural, An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Breast Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who have Progressed While Receiving Herceptin-Containing Regimens, GSK	01/2003 - 01/2005
Extramural, Apoptosis and Small Cell Lung Cancer, Sylvester Comprehensive Cancer Center Sridhar Endowment Fund	01/2003 - 12/2003
Extramural, Phase II Trial of Twice Daily Oral Topotecan as Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed SCLC, GSK	01/2003 - 01/2006
Extramural, Phase II Trial of Concurrent Chemoradiation Therapy with Weekly Docetaxal Carboplatin and Radiation Followed By Consolidation Chemotherapy with Weekly Docetaxel and Carboplatin for Locally Advanced Non-Small Cell Lung Cancer, Aventis	01/2003 - 01/2006
Extramural, Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel with Doxorubicin and Cyclophosphamide Following by Docetaxel and Trastuzumab and with Docetaxel, Platinum Salt and Trastuzumab in the Adjuvant Treatment of Node Positive and High Risk Node Negative Patients with Operable Breast Cancer Containing the Her2neu Alteration (BCIRG 006), BCIRG	01/2002 - 01/2007
Extramural, BAG-1 in Breast and Lung Cancer, University of Miami, Miami, Florida, USA	01/2002 - 01/2007
Extramural, A Multicenter, Phase III, Randomized Trial Comparing Docetaxel (Taxotere) And Trastuzumab (Herceptin) with Docetaxel (Taxotere), Platinum Salt (Cisplatin Or Carboplatin) And Trastuzumab (Herceptin) As First Line Chemotherapy For Patients with Advanced Breast Cancer Containing HER-2 Gene Amplification (BCIRG 007), BCIRG	01/2002 - 01/2006
Extramural, ACOG 9802 and ACOG 9803 Protocols, AMGEN	01/1999 - 01/2000
Extramural, Health Canada, Provincial Systemic Program	01/1999 - 01/2000
Extramural, Expression of BAG-1 in Breast Cancer, NCIC Operating Grant	01/1999 - 01/2002
Extramural, Hormones, BAG-1 and HPV16 in Cervical Oncogenesis and Apoptosis, MRC Operating Grant	01/1998 - 01/1999
Extramural, Enhancement of Tumor-specific Delivery of Anticancer Drugs and Other Apoptotic Mediators by Lipoprotein Particles, MRC Operating Grant	01/1997 - 01/2000
Extramural, Oncogenesis of Cervical Cells and Genes, HPV 16, HPV 18 and Environment, NCIC Operating Grant	01/1997 - 01/2000
Extramural, Transcription Regulation by BAG-1 for Human JC Virus, HPV and Cancer, MRC Operating Grant	01/1996 - 01/1999
Extramural, N/A, Newfoundland Cancer Foundation Research Fund	01/1995 - 01/1997
Extramural, N/A, Memorial University Research Start-up Fund	01/1995 - 01/1997

Tang, Shou C., M.D.

Education

Current Positions

Education

Specialty Certification Licensure

Academic Appointments or Other Previous Appointments

Honors, Awards, and Recognition

Professional Membership and Service

Committee Service

Community Service

Other Service

Sponsored Program Funding

Publications

2017 American Society of Clinical Oncology (ASCO) Presentation

2017 American Society of Clinical Oncology (ASCO) Conference Presentation

Proceedings of the American Association for Cancer Research

Letter

Journal Article

Abstracts

Book Chapter

Book

Clinical Trial

Presentations

Teaching Experience

Directed Student Learning

Fellows supervised

Biography

Services & Procedures